ARTICLE IN PRESS

Table 2
armA and *rmtB* alleles detected in clinical isolates of Gram-negative bacilli isolated in 2003 and in 2005

Species	No. of isolates[a]							
	September 2003				June 2005			
	Total	ARB or AMK I/R	*armA* allele positive	*rmtB* allele positive	Total	ARB or AMK I/R	*armA* allele positive	*rmtB* allele positive
E. coli	30	2	0	0	54	9	3	0
K. pneumoniae	30	14	9	1	40	12	5[b]	0
C. freundii	15	3	1	0	7	1	0	0
E. cloacae	15	4	2	0	17	0	NT	NT
S. marcescens	14	6	4	0	7	2	0	0
Acinetobacter spp.	15	4	2[c]	0	33	26	14[c]	0
P. aeruginosa	30	9	0	0	58	18	0	0
Total	148	42	18	1	216	68	22	0

ARB = arbekacin; AMK = amikacin; I/R = intermediate or resistant; NT = not tested.
[a] Consecutive isolates by each indicated species in 2003 and consecutive isolates by all indicated species in 2005.
[b] One *K. pneumoniae* isolate in 2005 had $bla_{CTX\text{-}M\text{-}14}$ allele.
[c] All *armA* allele-positive isolates were identified to be *A. baumannii*.

final extension at 72 °C for 6 min; for $bla_{CTX\text{-}M}$, 94 °C for 5 min followed by 30 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min, and a final extension at 72 °C for 7 min. Plasmid-mediated AmpC β-lactamase genes were amplified as previously reported (Lee et al., 2005).

All *armA* and *rmtB* allele-positive isolates were tested for ESBL production by a double-disk synergy test using ceftazidime, cefotaxime, aztreonam, cefepime, and amoxicillin–clavulanate disks (Pitout et al., 2003). Polymerase chain reaction (PCR) was performed to detect the $bla_{CTX\text{-}M}$ gene in the ESBL-producing isolates and to detect the plasmid-mediated AmpC β-lactamase gene in cefoxitin-nonsusceptible *E. coli* and *K. pneumoniae* isolates (Perez-Perez and Hanson, 2002). Imipenem-nonsusceptible isolates were tested for metallo-β-lactamase production by the imipenem disk Hodge (cloverleaf) test and the imipenem and ethylenediaminetetraacetic acid (EDTA) plus sodium mercaptoacetic acid (SMA) double-disk synergy test (Lee et al., 2003).

2.3. Conjugation and pulsed-field gel electrophoresis

An agar mating method was used to transfer high-level aminoglycoside resistance from randomly selected clinical isolates to an azide-resistant *E. coli* J53 recipient. Azide

Table 3
Comparison of MICs of aminoglycosides for *armA* or *rmtB* allele-positive and allele-negative Gram-negative bacilli

Species (no. of isolates tested)	Antimicrobial agent	*armA* or *rmtB* allele-positive isolates			*armA* or *rmtB* allele-negative isolates[a]		
		MIC (μg/mL)			MIC (μg/mL)		
		Range	50%	90%	Range	50%	90%
Enterobacteriaceae		(*n* = 25)[b]			(*n* = 10)[c]		
	Arbekacin	512 to >1024	>1024	>1024	1 to 64	8	64
	Amikacin	>1024	>1024	>1024	1 to 64	32	32
	Kanamycin	>1024	>1024	>1024	2 to 1024	256	1024
	Tobramycin	512 to >1024	>1024	>1024	1 to 128	32	64
	Gentamicin	256 to >1024	1024	>1024	1 to 512	1	256
	Netilmicin	>1024	>1024	>1024	1 to 256	128	256
	Isepamicin	512 to >1024	>1024	>1024	1 to 8	2	4
	Spectinomycin	≤8 to >1024	512	>1024	8 to >1024	256	>1024
	Streptomycin	≤8 to 512	256	512	4 to 1024	128	512
Acinetobacter spp.		(*n* = 16)[d]			(*n* = 9)		
	Arbekacin	1024 to >1024	>1024	>1024	8 to 32	16	32
	Amikacin	>1024	>1024	>1024	32 to 256	64	256
	Kanamycin	>1024	>1024	>1024	16 to >1024	>1024	>1024
	Tobramycin	>1024	>1024	>1024	8 to 128	128	128
	Gentamicin	>1024	>1024	>1024	64 to 256	256	256
	Netilmicin	>1024	>1024	>1024	128 to >1024	>1024	>1024
	Isepamicin	512 to >1024	>1024	>1024	32 to 512	128	512
	Spectinomycin	>1024	>1024	>1024	256 to >1024	>1024	>1024
	Streptomycin	512 to >1024	>1024	>1024	512 to >1024	1024	>1024

[a] Arbekacin- or amikacin-nonsusceptible isolates by disk diffusion test.
[b] Number of isolates were *K. pneumoniae* 15, *S. marcescens* 4, *E. coli* 3, *E. cloacae* 2, and *C. freundii* 1.
[c] All isolates were *K. pneumoniae*.
[d] All *armA* or *rmtB* allele-positive isolates were identified to be *A. baumannii*.

ARTICLE IN PRESS

100 μg/mL and amikacin 30 μg/mL were used to select for transconjugants.

Plugs of genomic DNA were prepared according to the protocols from the manufacturer of the CHEF-DR II system (Bio-Rad, Hercules, CA) and digested using *Sma*I for isolates of *Acinetobacter baumannii* and *Xba*I for isolates of Enterobacteriaceae. Pulsed-field gel electrophoresis (PFGE) was performed for 20 h at 6 V with a 3-s initial pulse and a 10-s final pulse for *A. baumannii*; pulses of 0.5 and 60 s were used for other species. After ethidium bromide staining, the DNA band patterns were analyzed using the UVIband/Map software (UVItech, Cambridge, United Kingdom) to generate a dendrogram that was based on the unweighted pair group method using an arithmetic average from the Dice coefficient.

3. Results and discussion

In the 1st phase study in 2003, to determine presence of Gram-negative bacilli with 16S rRNA methylase-mediated high level aminoglycosides resistance, we detected *armA* and *rmtB* alleles by PCR in 18 isolates and 1 isolate, respectively, of 42 strains, for which arbekacin MICs were 16 to >128 μg/mL. Most *armA* allele-positive isolates were *K. pneumoniae* (Table 2). In the 2nd phase study in 2005, to determine persistence of the resistance, we detected *armA* alleles in 3, 5, and 14 isolates of *E. coli*, *K. pneumoniae*, and *A. baumannii*, respectively, among 68 amikacin- or arbekacin-nonsusceptible isolates by the disk test. It is interesting that *armA* allele-positive *A. baumannii* became predominant and that *rmtA* allele was not detected, although it was present in *P. aeruginosa* isolates from Japan (Yamane et al., 2005; Yokoyama et al., 2003). High-level aminoglycoside resistance was transferred from 1 strain each of *E. coli*, *K. pneumoniae*, *Enterobacter cloacae*, and *Citrobacter freundii*, but not from *S. marcescens* and *A. baumannii* isolates (data not shown). Partial sequencing of nucleotides confirmed the amplicons from 1 isolate each of all 4 species, and 1 transconjugant had *armA* alleles (data not shown).

The MIC_{50}s of all aminoglycosides, including arbekacin and amikacin, but not streptomycin and spectinomycin, were ≥1024 μg/mL for *armA* and *rmtB* allele-positive isolates of Enterobacteriaceae (Table 3). 16S rRNA

Table 4
Pulsed-field gel electrophoresis types of endonuclease-restricted genomic DNA and antimicrobial susceptibility of *armA* or *rmtB* allele-positive Gram-negative bacilli

Isolates with alleles of		PFGE type	DDS test	Antimicrobial susceptibility				YMC strain no.
				FOX (P-M AmpC)	IPM	MEM	LVX	
K. pneumoniae	*armA*	A1	Pos	R (CMY-2)	I	I	R	03/9/U1015
	armA	A1	Pos	R (CMY-2)	S	S	R	03/9/R533, 03/9/U818, 03/9/U840, 03/9/U1041
	armA	A1	Neg	R (CMY-2)	S	S	R	03/9/T86, 03/9/U959
	armA	A2	Pos	R (CMY-2)	R	R	R	03/9/R615
	armA	A3	Pos	R (DHA-1)	S	S	R	03/9/R547
	armA	B	Pos	R (DHA-1)	S	S	R	05/6/U1062K[a]
	armA	C1	Pos[b]	I (Neg)	S	S	R	05/6/U1162
	armA	C2	Pos	R (Neg)	S	S	R	05/6/P359
	armA	D	Pos	R (Neg)	S	S	S	05/6/P300
	rmtB	E	Pos	S (NA)	S	S	S	03/9/U756
	armA	F	Neg	R (DHA-1)	S	S	R	05/6/U1190
E. coli	*armA*	A	Pos	R (DHA-1)	S	S	R	05/6/U1062E[a]
	armA	B	Neg	R (Neg)	S	S	R	05/6/U1079
	armA	C	Pos	R (DHA-1)	S	S	R	05/6/U1173
E. cloacae	*armA*	A	Pos	NA	S	S	R	03/9/P218
	armA	B	Neg	NA	S	S	S	03/9/P254
C. freundii	*armA*	NT	Neg	NA	S	S	I	03/9/T109
S. marcescens	*armA*	NT	Pos	NA	S	R	R	03/9/U630, 03/9/U1649
	armA	NT	Pos	NA	S	I	R	03/9/U837, 03/9/U881
A. baumannii	*armA*	A1, 3–6	Neg	NA	R	R	R	03/9/R496, 05/6/R672, 05/6/T127, 05/6/R667, 05/6/P365, 05/6/R912
	armA	A2	Neg	NA	I	R	R	05/6/R660, 05/6/R749, 05/6/R752, 05/6/R873, 05/6/R891, 05/6/U990
	armA	A7	Pos	NA	S	R	R	05/6/R783
	armA	B	Neg	NA	S	S	R	03/9/P225
	armA	C1	Neg	NA	I	R	R	05/6/R933
	armA	C2	Neg	NA	S	S	I	05/6/P364

DDS = double-disk synergy test for ESBL; FOX = cefoxitin; P-M = plasmid-mediated; IPM = imipenem; MEM = meropenem; LVX = levofloxacin; Pos = positive; Neg = negative; NA = not applicable; S = susceptible; I = intermediate; R = resistant; YMC = Yonsei Medical Center.

[a] An isolate each of *E. coli* and *K. pneumoniae* were isolated from a patient.

[b] A $bla_{CTX\text{-}M\text{-}14}$ allele was detected.

ARTICLE IN PRESS

Table 5
Comparison of efficiency of arbekacin and amikacin disk diffusion test to screen *armA* and *rmtB* allele-positive Gram-negative bacilli

armA or *rmtB*	Organism (no. of isolates)	Aminoglycosides	No. of isolates with inhibition zone diameter (mm)[a]														
			6	7	8	9	10	11	12	13	14	15	16	17	18	19	≥20
Positive	Enterobacteriaceae (15)	Arbekacin	**15**														
		Amikacin	**14**	**1**													
	A. baumannii (14)	Arbekacin	**12**		**2**												
		Amikacin	**14**														
Negative	Enterobacteriaceae (15)	Arbekacin							1	4	2	1	1	2	1	2	1
		Amikacin							2	4	4	2	2				1
	Acinetobacter spp. (12)	Arbekacin	2			2	2	1	4		1						
		Amikacin	**11**				1										
	P. aeruginosa (17)	Arbekacin			1			1	1	1	1	1		2	1		8
		Amikacin	7	1			1	1			1	2	3			1	

[a] Data in boldface indicate number of isolates resistant to arbekacin or amikacin.

methylases do not confer high-level resistance to streptomycin. The MICs of the aminoglycosides were much lower for arbekacin- or amikacin-nonsusceptible isolates that were 16S rRNA methylase gene negative. MICs for 4 transconjugants from 1 isolate each of *K. pneumoniae*, *E. coli*, *C. freundii*, and *E. cloacae* were all ≥ 1024 μg/mL, except for those of streptomycin and spectinomycin, which were 256 to 512 μg/mL and 32 to >1024 μg/mL, respectively (data not shown).

Among the 41 *armA* or *rmtB* allele-positive isolates, 12 (80.0%) of 15 *K. pneumoniae*, 2 of 3 *E. coli*, 1 of 2 *E. cloacae*, and all 4 *S. marcescens* isolates were double-disk synergy test positive, indicating production of ESBLs (Table 4). The *armA* gene was reported to be linked to bla_{CTX-M} gene in a *K. pneumoniae* isolate (Galimand et al., 2003), and in a Taiwanese study, 94.3% of *armA*- or *rmtB*-positive *E. coli* and *K. pneumoniae* isolates had CTX-M type ESBLs (Yan et al., 2004). However, in our study, the $bla_{CTX-M-14}$ allele was detected in only 1 *K. pneumoniae* isolate (case 12), suggesting that 16S rRNA methylase gene is not always linked to bla_{CTX-M}. In a Taiwanese study, 2 *armA*-positive *E. coli* isolates had the plasmid-mediated AmpC β-lactamase CMY-2 (Yan et al., 2004). Of the 18 isolates of *armA* or *rmtB* allele-positive *K. pneumoniae* and *E. coli* in our study, 16 were resistant to cefoxitin, and among them, 8 and 5 were positive for bla_{CMY-2} and bla_{DHA-1} alleles, respectively (Table 4). This finding may not be unusual because our previous study in 2003 showed that among the cefoxitin-resistant isolates, 32.7% of *E. coli* and 76.2% of *K. pneumoniae* had either bla_{CMY-2} or bla_{DHA-1} alleles (Lee et al., 2006b). Two of 15 *K. pneumoniae* isolates and 13 (81.3%) of 16 *A. baumannii* isolates were nonsusceptible to imipenem by the disk diffusion test, but they were negative to the imipenem disk Hodge test, and the imipenem and EDTA–SMA double-disk synergy test (Lee et al., 2003), indicating nonproduction of a metallo-β-lactamase (data not shown). The levofloxacin resistance rates of *armA* or *rmtB* allele-positive isolates of *K. pneumoniae* and *A. baumannii* were much higher, that is, 86.7% and 93.8%, respectively (Table 4), compared with

Table 6
Clinical features of the patients from whom *armA* or *rmtB* allele-positive isolates were detected

Age (year) (no. of patients)	Male/female	Admission wards		Underlying diseases or clinical conditions					Sources of isolation		
		ICUs	Others	Malignancy	IC bleeding	UGI bleeding	Paraplegia	Other conditions	Sputum	Urine	Wound
< 15 (4)	1/3	2	2	1	0	0	0	One each of spleen rupture, dextrocardia, and foot injury	1	1	2
15–29 (2)	1/1	1	1	0	0	0	1	SLE	0	0	2
30–39 (4)	4/0	3	1	1	1	1	0	Septic shock	2	2	0
40–49 (3)	3/0	2	1	0	2	0	0		0	2	1
50–59 (9)	6/3	6	3	1	3	1	0	One each of DM, liver cirrhosis, epilepsy, and herniated cervical disk	4	3	2
60–69 (10)	5/5	5	4	4	3	0	1	One each of dermatomyositis and pulmonary edema	5	5	0
> 70 (8)	5/3	5	4	0	2	1	2	One each of septic shock, cholecystitis, and pneumonia	5	3	0
Total (40)	25/15	24	16	7	11	3	4		17	16	7

ICU = intensive care unit; IC = intracranial; UGI = upper gastrointestinal; SLE = systemic lupus erythematosus; DM = diabetes mellitus.

ARTICLE IN PRESS



Fig. 1. Pulsed-field gel electrophoresis patterns of endonuclease-restricted genomic DNAs from 16S rRNA methylase-positive isolates of *K. pneumoniae* (A) and *A. baumannii* (B). Seven of 10 *armA* gene-positive *K. pneumoniae* isolates from 2003 showed identical PFGE patterns (A1). Among the 14 *A. baumannii* isolates with *armA* genes from 2005, 6 showed identical patterns (A2).

those of 31% and 60%, respectively, in 2003, at the hospital (unpublished data). The resistance rates of *armA* or *rmtB* allele-positive isolates to trimethoprim–sulfamethoxazole and tetracycline were 100% for *A. baumannii*, and 76% and 72%, respectively, for Enterobacteriaceae (data not shown). Correlation of inhibition zone diameter of <9 mm and presence of *armA* or *rmtB* allele (Table 5) showed that arbekacin was more useful than amikacin for screening isolates with these resistance determinants; positive rates were 29 of 32 isolates (90.6%) with arbekacin compared with 29 of 48 isolates (60.4%) with amikacin.

Retrospective analysis of clinical features showed that the *armA* and *rmtB* allele-positive isolates were from 25 (62.5%) male and 15 (37.5%) female patients, and 27 (67.5%) were older than 49 years (Table 6). All were inpatients with various morbidities, and 24 (60.0%) were admitted to intensive care units. The impact of antimicrobial resistance on the clinical outcomes of study patients was not evaluated because many patients received various antimicrobial agents, and the etiologic role of the sputum isolates is difficult to determine (Thomson and Miller, 2003). The sources of the isolates were sputum (42.5%), urine (40.0%), and wound (17.5%). Seven of 10 *armA* gene-positive *K. pneumoniae* isolates from 2003 showed identical PFGE patterns (A1), suggesting that a small outbreak occurred from a clone (Fig. 1A). However, all 5 isolates in 2005 had different patterns, suggesting that the horizontal spread of the resistance determinant had occurred. The presence of *armA* allele-positive *E. coli* and *K. pneumoniae* in a patient (case No. 15) suggested that in vivo horizontal transfer of the resistance determinant had possibly occurred. Among the 14 *A. baumannii* isolates in 2005, 6 showed identical patterns (Fig. 1B and A2), again suggesting a clonal outbreak. Isolates in 2003 and 2005 showed distantly related patterns suggesting that horizontal spread of the resistance had occurred.

In conclusion, 16S rRNA methylase-producing isolates of *K. pneumoniae* and *A. baumannii* were relatively more prevalent in a hospital in Korea than in other countries. 16S rRNA methylase-producing isolates were highly resistant to arbekacin and amikacin, and are mostly coresistant to levofloxacin. Most *K. pneumoniae* isolates also produced ESBLs and plasmid-mediated AmpC β-lactamases, but $bla_{\text{CTX-M}}$ was detected in only 1 isolate. Most *A. baumannii* isolates were also nonsusceptible to imipenem or meropenem. Further studies are urgently required to determine the resistance prevalence in other Korean hospitals to establish measures to control further spread of the resistance.

Acknowledgments

This work was supported in part by the Brain Korea 21 Project for Medical Sciences, Yonsei University, Seoul, South Korea, in 2004. The authors thank Myungsook Kim for collecting the isolates and Younghee Seon and Chasoon Lee for technical assistance.

References

Clinical and Laboratory Standards Institute (2006) Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement, M100-S16. Wayne (PA): CLSI.

Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y (2004) Plasmid-mediated 16S rRNA methylase in *Serratia marcescens* conferring high-level resistance to aminoglycosides. *Antimicrob Agents Chemother* 48:491–496.

Farmer III JJ (2003) Enterobacteriaceae: introduction and identification. In *Manual of clinical microbiology*. Eds, PR Murray, EJ Baron, JH Jorgensen, MA Pfaller and RH Yolken, (8th ed.). Washington (DC): American Soc Microbiol, pp 636–653.

Galimand M, Courvalin P, Lambert T (2003) Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. *Antimicrob Agents Chemother* 47:2565–2571.

Galimand M, Sabtcheva S, Courvalin P, Lambert T (2005) Worldwide disseminated *armA* aminoglycoside resistance methylase gene is borne by composite transposon Tn*1548*. *Antimicrob Agents Chemother* 49:2949–2953.

Gonzalez-Zorn B, Catalan A, Escudero JA, Dominguez I, Teshager T, Porrero C, Moreno MA (2005) Genetic basis for dissemination of *armA*. *J Antimicrob Chemother* 56:583–585.

Hancock REW (1981) Aminoglycoside uptake and mode of action—with special reference to streptomycin and gentamicin. *J Antimicrob Chemother* 8:249–276.

Hooper DC (2005) Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. *Clin Infect Dis* 40:1811–1817.

Kondo S, Hotta K (2005) Semisynthetic aminoglycoside antibiotics; development and enzymatic modifications. *J Infect Chemother* 5:1–9.

Lee K, Lim YS, Yong D, Yum JH, Chong Y (2003) Evaluation of the Hodge test and the imipenem–EDTA double disk synergy test for differentiating metallo-β-lactamase–producing isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol* 41:4623–4629.

Lee K, Hong SG, Park YJ, Lee HS, Song W, Jeong J, Yong D, Chong Y (2005) Evaluation of phenotypic screening methods for detecting plasmid-mediated AmC β-lactamases–producing isolates of *Escherichia coli* and *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis* 53:319–323.

Lee K, Lee M, Shin JH, Lee MH, Kang SH, Park AJ, Yong D, Chong Y, KONSAR participants (2006) Prevalence of plasmid-mediated AmpC β-lactamases in *Escherichia coli* and *Klebsiella pneumoniae* in Korea. *Microbial Drug Resist* 12:44–49.

Lee K, Park KH, Jeong SH, Lim HS, Shin JH, Yong D, Ha G-Y, Chong Y (2006) Further increase of vancomycin-resistant *Enterococcus faecium*, amikacin- and fluoroquinolone-resistant *Klebsiella pneumoniae*, and imipenem-resistant *Acinetobacter* spp. in Korea: 2003 KONSAR surveillance. *Yonsei Med J* 47:43–54.

Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM (1999) Aminoglycosides: activity and resistance. *Antimicrob Agents Chemother* 43:727–737.

Perez-Perez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol* 40:2153–2162.

Pitout JDD, Reisbig MD, Venter EC, Church DL, Hanson ND (2003) Modification of the double-disk test for detection of Enterobacteriaceae producing extended-spectrum and AmpC β-lactamases. *J Clin Microbiol* 41:3933–3935.

Sader HS, Fritsche TR, Jones RN (2005) Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program 1998–2003. *Diagn Microbiol Infect Dis* 52:265–273.

Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG (2003) *Acinetobacter*, *Chryseobacterium*, *Moraxella*, and other nonfermentative gram-negative rods. In *Manual of clinical microbiology*. Eds, PR

You EJ Baron, JH Jorgensen, MA Pfaller, and RH Yolken, (8th ed.). Washington (DC): American Soc Microbiol, pp 749–779.

Shaw KJ, Rather PN, Hare RS, Miller GH (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. *Microb Rev* 57:138–163.

Thomson RB, Miller JM (2003) Specimen collection, transport, and processing: bacteriology. In *Manual of clinical microbiology*. Eds, PR Murray, EJ Baron, JH Jorgensen, MA Pfaller, and RH Yolken, (8th ed.). Washington (DC): American Soc Microbiol, pp 286–330.

Yamane K, Doi Y, Yokoyama K, Yagi T, Kurokawa H, Shibata N, Shibayama K, Kato H, Arakawa Y (2004) Genetic environments of *rmtA* gene in *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 48:2069–2074.

Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y (2005) Global spread of multiple aminoglycoside resistance genes. *Emerg Infect Dis* 11:951–953.

Yan J-J, Wu J-J, Ko W-C, Tsai S-H, Chung C-L, Wu H-M, Lu Y-J, Li J-D (2004) Plasmid-mediated 16S rRNA methylase conferring high-level aminoglycoside resistance in *Escherichia coli* and *Klebsiella pneumoniae* isolates from two Taiwanese hospitals. *J Antimicrobial Chemother* 54:1007–1012.

Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, Yagi T, Kato H, Arakawa Y (2003) Acquisition of 16S rRNA methylase gene in *Pseudomonas aeruginosa*. *Lancet* 362:1888–1893.

Yoshizawa S, Fourmy D, Puglisi JD (1999) Recognition of the codon–anticodon helix by ribosomal RNA. *Science* 285:1722–1725.

You I, Kariyama R, Zervos MJ, Kumon H, Chow JW (2000) In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant *Staphylococcus aureus*. *Diagn Microbiol Infect Dis* 36:37–41.

APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Nov. 2006, p. 6955–6964 Vol. 72, No. 11
0099-2240/06/$08.00+0 doi:10.1128/AEM.00934-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Genetic Analysis of Bacteriocin 43 of Vancomycin-Resistant *Enterococcus faecium*▽

Daisuke Todokoro,[1,2] Haruyoshi Tomita,[1]* Takako Inoue,[1] and Yasuyoshi Ike[1,3]

Department of Bacteriology and Bacterial Infection Control,[1] Department of Ophthalmology,[2] and Laboratory of Bacterial Drug Resistance,[3] Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan

Received 20 April 2006/Accepted 9 August 2006

A total of 636 vancomycin-resistant *Enterococcus faecium* (VRE) isolates obtained between 1994 and 1999 from the Medical School Hospital of the University of Michigan were tested for bacteriocin production. Of the 277 (44%) bacteriocinogenic strains, 21 were active against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *Listeria monocytogenes*. Of those 21 strains, a representative bacteriocin of strain VRE82, designated bacteriocin 43, was found to be encoded on mobilizable plasmid pDT1 (6.2 kbp). Nine open reading frames (ORFs), ORF1 to ORF9, were presented on pDT1 and were oriented in the same direction. The bacteriocin 43 locus (bac43) consists of the bacteriocin gene *bacA* (ORF1) and the immunity gene *bacB* (ORF2). The deduced *bacA* product is 74 amino acids in length with a putative signal peptide of 30 amino acids at the N terminus. The *bacB* gene encodes a deduced 95-amino-acid protein without a signal sequence. The predicted mature BacA protein (44 amino acids) showed sequence homology with the membrane-active class IIa bacteriocins of lactic acid bacteria and showed 86% homology with bacteriocin 31 from *E. faecalis* YI717 and 98% homology with bacteriocin RC714. Southern analysis with a bac43 probe of each plasmid DNA from the 21 strains showed hybridization to a specific fragment corresponding to the 6.2-kbp EcoRI fragment, suggesting that the strains harbored the pDT1-like plasmid (6.2 kb) which encoded the bacteriocin 43-type bacteriocin. The bac43 determinant was not identified among non-VRE clinical isolates.

Bacteriocins are produced by a wide variety of gram-positive and gram-negative bacteria. They are bacterial proteins which inhibit the growth of other bacteria that are closely related to the producer strains, and they usually exhibit a relatively narrow spectrum of activity. Bacteriocins are thought to provide the producer strain with an ecological or selective advantage over other strains. Bacteriocin production has been described for several genera of lactic acid bacteria (LAB) (12, 33). LAB bacteriocins can be classified into two main classes (34), i.e., class I, modified bacteriocins (the lantibiotics) and class II, the small, heat-stable nonlantibiotics, which are divided into subgroups IIa, pediocin-like bacteriocins with a strong antilisterial effect, and IIb, non-pediocin-like bacteriocins and those with two peptides that require the complementary action of both peptides for full antimicrobial activity. In the genus *Enterococcus*, *Enterococcus faecalis* and *E. faecium* bacteriocins have been genetically and biochemically well characterized. *E. faecalis* bacteriocins include the β-hemolysin/bacteriocin (cytolysin) (9, 17, 18, 21, 23, 24), the peptide antibiotic AS-48 (28), bacteriocin 21 (Bac 21) (43), and Bac 31 (42). These bacteriocins have been identified from *E. faecalis* clinical isolates (29, 42, 43, 47). The well-characterized *E. faecium* bacteriocins have been isolated from food grade organisms (6, 19) and include enterocins A (1), B (3), P (4), I (15), L50A, and L50B (5). These bacteriocins belong to the LAB class II bacteriocins and are active against *Listeria monocytogenes* (34). Enterocins A and P are pediocin-like bacteriocins (12).

In contrast to the bacteriocins obtained from *E. faecalis* clinical isolates, there have been few reports describing either the bacteriocins present in *E. faecium* clinical isolates, including vancomycin-resistant *E. faecium* (VRE), or the relationship between the bacteriocin determinant and a plasmid (10, 11, 25).

In our previous study (25), a total of 636 VRE strains were tested for bacteriocin production against various indicator strains. Two hundred seventy-seven (44%) of the 636 strains tested were bacteriocinogenic. The bacteriocinogenic strains were classified into four groups on the basis of their bacteriocin activity. Of the 277 bacteriocin producers tested for activity against enterococci, 21 strains (3.3%) showed bacteriocin activity against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, *L. monocytogenes*, and *L. denitrificans*; 193 strains (69.7%) showed activity against *E. faecium*, *E. hirae*, and *E. durans*; and 4 strains (0.6%) showed activity against *E. faecalis*. The remaining 59 bacteriocinogenic strains produced a small zone of bacteriolysis against *E. hirae*. In this study, we present an analysis of Bac 43, which was active against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, *L. monocytogenes*, and *L. denitrificans*.

MATERIALS AND METHODS

Bacteria, media, and reagents. The strains and plasmids used in this study are listed in Table 1. A total of 640 VRE clinical isolates were obtained from different patients who had been admitted to the University of Michigan Medical School Hospital, Ann Arbor, between 1994 and 1999. The bacteriocinogenic strains among these isolates were previously classified into three groups on the basis of their bacteriocin activity (25). Of the 636 VRE clinical isolates tested, 21 strains showing bacteriocin activity against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, *L. monocytogenes*, and *L. denitrificans* were used in this study. The indicator strains used for the bacteriocin assay were *Staphylococcus aureus* FDA209P (32), *E. faecalis* FA2-2 (8) and OG1S (7), *E. faecium* BM4105RF (44), *E. hirae* ATCC 9790 (38), *E. durans* ATCC 49135, *E. raffinosus* JCM8733, *E.*

* Corresponding author. Mailing address: Department of Bacteriology and Bacterial Infection Control, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan. Phone: 81-27-220-7992. Fax: 81-27-220-7996. E-mail: tomitaha@med.gunma-u.ac.jp.

▽ Published ahead of print on 21 August 2006.

TABLE 1. Bacterial strains and plasmids used in this study

Strains and plasmid	Genotype or phenotype	Description	Reference or source
Strains			
Enterococcus faecalis			
FA2-2	Rif^r Fus^r	Derivative of JH2	8
JH2SS	Str^r Spc^r	Derivative of JH2	41
OG1-10 (OG1S)	Str^r	Derivative of OG1	7
Enterococcus faecium			
BM4105RF	Rif^r Fus^r	Derivative of plasmid-free *E. faecium* BM4105	44
BM4105SS	Str^r Spc^r	Derivative of plasmid-free *E. faecium* BM4105	44
VRE82	pDT1(Bac 43) Kam^r Gen^r Tei^r Van^r Amp^r	Bacteriocinogenic clinical isolate	44, this study
Enterococcus hirae ATCC 9790	Penicillin susceptible	Wild type	38
Enterococcus durans ATCC 49135	Penicillin susceptible	Wild type	
Enterococcus raffinosus JCM8733	Penicillin susceptible	Wild type	
Enterococcus gallinarum BM4174	Penicillin susceptible	Wild type	27
Staphylococcus aureus FDA209P	Penicillin susceptible	Wild type	32
Escherichia coli			
DH5α	*recA1 endA1 gyrA96 thi-1 relA1 hsdR17 supE44* φ80 *lacZ*Δ M15		Bethesda Research Laboratories
TH688	CSH57b *thr*::Tn*5*		40
Plasmids			
pDT1	Bac 43	Mobilizable plasmid (6.2 kb)	This study
pAM401	Cm^r Tc^r	*E. coli-E. faecalis* shuttle vector	46
pHTβ	Van^r	pMG1-like highly conjugative plasmid (53.7 kb)	45
pUC18	Amp^r *lacZ*	*E. coli* vector	Nippon Gene Co.

gallinarum BM4174 (27), *S. agalactiae*, *S. pyogenes*, and *L. monocytogenes*. *Enterococcus* strains were grown in Todd-Hewitt broth (THB; Difco, Detroit, Mich.) or antibiotic medium 3 (Difco). *Escherichia coli* strains were grown in Luria-Bertani medium. Solid and soft media were prepared by the addition of 1.5% or 0.75% (wt/vol) agar, respectively. All cultures were grown at 37°C. Antibiotics were used at the following concentrations: ampicillin, 100 μg/ml; chloramphenicol, 20 μg/ml for *Enterococcus* and 50 μg/ml for *E. coli*; vancomycin, 12.5 μg/ml; rifampin, 25 μg/ml; fusidic acid, 25 μg/ml; streptomycin, 250 μg/ml; gentamicin, 250 μl/ml; spectinomycin, 250 μg/ml; kanamycin, 500 μg/ml for *Enterococcus* and 40 μg/ml for *E. coli*; tetracycline, 12.5 μg/ml.

Soft-agar assay for bacteriocin production and immunity. The bacteriocin production assay was performed as described previously (24). Fifty microliters of an overnight culture of the indicator strains grown in antibiotic medium 3 was added to 5 ml of molten soft agar (0.75%), which was then poured onto a THB plate. After solidification, each strain to be tested was inoculated into the soft agar with a toothpick. The halos of inhibition around the inoculated test strains were monitored after overnight culture.

To test immunity to the bacteriocin, a modification of the bacteriocin production test was performed. The indicator strain was used to test immunity. Inhibition of halo formation means that the indicator strain has immunity against the bacteriocin produced by the inoculated strain.

Mating procedures. Solid-surface matings were performed as previously described (44). Overnight cultures of the donor and the recipient were mixed at a donor/recipient ratio of 1:10, and 10 μl of the mixed culture was dripped onto THB agar without drug. The plates were then incubated overnight (18 h) at 37°C. After incubation, the bacteria grown on the agar plates were scraped off and transferred into 1 ml of fresh broth and then 0.1-ml samples of the suspension were inoculated onto the appropriate selective agar plates. Colonies were counted after 48 h of incubation at 37°C.

Isolation and manipulation of plasmid DNA. Plasmid DNA was isolated by the alkaline lysis method (36). Plasmid DNA was treated with restriction enzymes and subjected to agarose gel electrophoresis for analysis of DNA fragments. Restriction enzymes were obtained from Nippon Gene (Toyama, Japan); New England Biolabs, Inc. (Massachusetts); and Takara (Tokyo, Japan) and used in accordance with the suppliers' specifications. Agarose was obtained from Wako Chemicals (Osaka, Japan) and used at a 0.8% agarose concentration in agarose gel electrophoresis. DNA fragments were eluted from agarose gels with the Wizard SV Gel and the PCR Clean-Up System (Promega Corporation, Madison, WI). The eluted fragments were ligated to dephosphorylated, restriction enzyme-digested vector DNA with the DNA Ligation Kit Ver.2 (Takara, Tokyo, Japan) and then introduced into *E. coli* by electrotransformation (16). Transformants were selected on Luria-Bertani medium agar containing suitable antibiotics.

PCR methodology. The PCR program, with an Ex *Taq* DNA polymerase (Takara), comprised 2 min at 95°C followed by 30 cycles of 2 min at 95°C, 2 min at 56°C, and 2 min at 72°C and then a final incubation at 4°C with a GeneAmp PCR system 9600 thermal cycler (Perkin-Elmer).

Determination of pDT1 restriction map. The restriction map of pDT1 was constructed by double digestion and analysis by agarose gel electrophoresis. The restriction enzymes EcoRI, HindIII, EcoRV, XbaI, and BamHI were used for digestion.

Generation of transposon insertional mutants. Tn*5* (Km^r) insertion into pDT1 was performed as described elsewhere (39, 42). pDT1 was introduced into *E. coli* K-12 TH688 (with Tn*5* in the *thr* locus) (40) by electrotransformation. Ten of the transformants were selected and spread onto selective medium containing 40 μg of kanamycin and 12.5 μg of tetracycline per ml, and the plates were left at room temperature for 10 days. The bacteria which grew on the selective plates were scraped off, and the plasmid DNA was then isolated and used to transform *E. coli* DH5α. The transformants were selected on plates containing kanamycin (40 μg/ml) and tetracycline (12.5 μg/ml) for selection of Tn*5* kanamycin resistance and pTD1-borne tetracycline resistance, respectively. The transformants were purified and examined to determine the specific location of Tn*5* within the plasmid. The precise location of the Tn*5* insertion was determined by direct nucleotide sequencing with a synthetic primer shown in Table 2, which hybridized to the end of Tn*5* (43).

DNA sequence analysis. Nucleotide sequence analysis was carried out as previously described (37). To determine the entire sequence of pDT1, shotgun sequencing was performed. Fragmented DNA libraries were constructed by sonication of EcoRI-digested pDT1, followed by ligation into the SmaI-digested pUC18 vector plasmid. pUC18 plasmids containing 0.5- to 1.0-kb inserts were used to transform *E. coli* DH5α. The resulting constructs were sequenced in both orientations with an ABI Prism 377 sequencer (Applied Biosystems). The BigDye Terminator Ver.1.1 cycle sequencing kit (Applied Biosystems) and primers 21M13 and M13Rev (Perkin-Elmer) were used for the sequencing reaction.

TABLE 2. Oligonucleotides used in this study

Primer	Sequence and restriction sites[a]	Description
Bac43-1	GAATTCAAAACTACTTTTTATGACG	Analysis of *bac* determinant
Bac43-2	GAATTCTAGGAACTTGTCTAGCTGG	
Bac43-5′	GAATTCTATGATAATTTTTCGGCTC	
Bac43-4′	GAATTCGATAGTCATCTATAGTTGC	
Bac43-6′	GAATTCAAGCCCATCCTCTATATAC	
Tn5	CAGATTTAGCCCAGTCGG	Analysis of Tn*5* insetion mutant
J1	GAGTATTGCAACTTGCTCGC	Analysis of EcoRI junction of pTD1
J2	GCTACAAGAAGTGGTTCGGC	
C	TTGGTACAGGCGTTACTTGG	Analysis of *bacA* gene
E2	ATCCGAATTCATAACCTCCCTACCACTACC	
H1	CGAAAAGGAAAAACAATCATG	Analysis of bac43 determinants
H2	TCCCATTTTCATTTTATTCC	
M1	AAGGGTGGGACTTATGAGCG	Analysis of *mob* genes
M2	TTGTTGGTAGTCTGCTCCTC	

[a] Underlined letters indicate restriction sites (GAATTC; EcoRI).

Open reading frame (ORF) analysis was performed with Genetyx, version 6.1 (Genetyx Corp., Tokyo, Japan). The DNA Data Bank of Japan (DDBJ; National Institute of Genetics, Mishima, Japan) was used for homology analysis of nucleotide and amino acid sequences.

Direct sequencing was performed to confirm the sequence near the EcoRI junction of pDT1 and the structures of the insertion and deletion mutants. The PCR products were eluted from agarose gels as described above and sequenced in both orientations with an ABI Prism 310 sequencer (Applied Biosystems). The BigDye Terminator Ver.1.1 cycle sequencing kit (Applied Biosystems) was used for the sequencing reaction with PCR primers (Table 2).

Deletion mutant analysis. The deletion mutants shown in Fig. 3 were constructed by PCR with pDT1 as the template. The primers used to construct each subclone are listed in Table 2. Subclones of pMG502, pMG503, pMG504, and pMG505 were constructed with primer pairs Bac43-1 and -5′, Bac43-1 and -4′, Bac43-2 and -5′, and Bac43-2 and -6′, respectively. PCR products were digested with EcoRI and cloned into shuttle vector pAM401. Each subclone was introduced into *E. faecalis* FA2-2 and tested in the soft-agar assay. The sequences of all subclones were confirmed by direct DNA sequencing.

Southern hybridization. Southern hybridization was performed with the digoxigenin (DIG)-based nonradioisotope system of Boehringer GmbH (Mannheim, Germany), and all procedures were based on the manufacturer's manual and standard protocols (36). Hybridization was performed overnight at 42°C in the presence of 50% formamide. The PCR product generated between primers C and E2 with the PCR DIG synthesis kit (Roche Diagnostics, Mannheim, Germany) was used as the probe for *bacA*. The nucleotide sequences of the primer pair are shown in Table 2. Signals were detected with the DIG chemiluminescence detection kit (Boehringer GmbH). CSPD (Boehringer GmbH) was used as a substrate for alkali phosphatase conjugated to the anti-DIG antibody.

Pulsed-field gel electrophoresis. Genomic DNA was prepared as previously described (31). A gel block containing genomic DNA was incubated overnight with 10 U of SmaI. Electrophoresis was then carried out with a 1% agarose gel with 0.5% Tris-borate-EDTA, and the settings applied were 1 to 21 s, 6 V/cm^2, and 20 h. The gel was stained with ethidium bromide for UV observation. The results were classified as closely related, possibly related, or different types (31).

Nucleotide sequence accession number. The nucleotide sequence data reported in this article are available from the DDBJ, EMBL, and GenBank nucleotide sequence databases under accession number AB178871.

RESULTS

Identification of a plasmid-coded bacteriocin active against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes*. Of the 277 (44%) bacteriocinogenic strains identified among a total of 636 VRE strains, 21 bacteriocinogenic strains that are active against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes* (3.3%) were used in this study. The drug resistance patterns of the 21 strains are shown in Table 3. The enterococcal bacteriocins are usually carried on plasmids, some of which are self-transferable and some of which can be mobilized by coresident conjugative plasmids. To examine whether bacteriocin production was cotransferred with drug resistance, mating experiments were performed between each of the 21 bacteriocinogenic strains and recipient strain *E. faecium* BM4105RF on a solid surface (filter mating). Vancomycin or gentamicin was used as a selective marker for transconjugants (Table 3), and rifampin and fusidic acid were used for counterselection against the donor strain. Vancomycin- or gentamicin-resistant transconjugants were obtained at frequencies of 10^{-5} to 10^{-8} per donor cell with 12 of the 21 strains (Table 3). Bacteriocin activities were examined in the transconjugants from each of these strains. The drug resistance transconjugants exhibited bacteriocin activities at a relatively high frequency (Table 3). The bacteriocin activities were identical to that of the donor strain. Of these bacteriocinogenic strains, VRE82 was chosen as a representative for further analysis. With the VRE and bacteriocinogenic *E. faecium* BM4105RF transconjugant of VRE82 as the initial donor, repeated experiments to transfer bacteriocin production were performed between *E. faecium* BM4105RF and *E. faecium* BM4105SS. Vancomycin resistance was used as a selective marker for the transconjugants. Vancomycin-resistant transconjugants were tested for bacteriocin activity against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes*. About 80 to 95% of the transconjugants were bacteriocinogenic and showed bacteriocin activity identical to that of donor strain VRE82, and the remaining transconjugants showed no bacteriocin activity. Plasmid DNA was isolated from each of the transconjugants, treated with the EcoRI restriction enzyme, and analyzed by agarose gel electrophoresis. All of the nonbacteriocinogenic vancomycin-resistant transconjugants exhibited two major bands, and all of the bacteriocinogenic and vancomycin-resistant transconjugants exhibited an additional DNA band with a molecular size of 6.2 kbp in their agarose gel electrophoresis profiles (Fig. 1).

The 6.2-kb EcoRI fragment obtained by agarose gel electrophoresis was eluted from the agarose gel and ligated with shuttle vector pAM401. The cloned 6.2-kbp EcoRI fragment was introduced into *E. coli* DH5α, and the clone pAM401::6.2-

TABLE 3. Drug resistance patterns of bacteriocinogenic strains and transferabilities of bacteriocin activity with drug resistance

Strain[a]	Drug resistance pattern[b]	Transfer frequency[c] (% of bacteriocinogenic transconjugants)	
		Vam^r	Gen^r
VRE74	Apc Gen Kan Tei Van	2×10^{-8} (50)	$<1 \times 10^{-8}$
VRE78	Apc Gen Kan Tei Van	2×10^{-6} (100)	$<1 \times 10^{-8}$
VRE82	Apc Gen Kan Tei Van	2×10^{-8} (90)	$<1 \times 10^{-8}$
VRE83	Apc Gen Kan Tei Van	2×10^{-7} (80)	$<1 \times 10^{-8}$
VRE94	Apc Gen Kan Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$
VRE252	Apc Gen Kan Tei Van	$<1 \times 10^{-8}$	4×10^{-8} (75)
VRE272	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	4×10^{-8} (100)
VRE278	Apc Gen Kan Str Tei Van	2×10^{-7} (75)	4×10^{-8} (5)
VRE319	Apc Gen Kan Str Tei Van	6×10^{-8} (100)	4×10^{-8} (35)
VRE330	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$
VRE351	Apc Gen Kan Str Tei Van	2×10^{-7} (75)	9×10^{-5} (8)
VRE367	Apc Kan Str Tei Van	1×10^{-7} (100)	NT[d]
VRE418	Apc Kan Str Tei Van	$<1 \times 10^{-8}$	NT
VRE419	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$
VRE424	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	3×10^{-8} (50)
VRE437	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$
VRE455	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$
VRE477	Apc Gen Kan Str Tei Van	$<1 \times 10^{-8}$	2×10^{-8} (75)
VRE506	Apc Kan Mino Tet Tei Van	$<1 \times 10^{-8}$	NT
VRE576	Apc Gen Kan Tet Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$
VRE595	Apc Gen Kan Tet Tei Van	$<1 \times 10^{-8}$	$<1 \times 10^{-8}$

[a] The strains exhibited bacteriocin activity against *E. faecalis*, *E. faecium*, *E. durans*, *L. monocytogenes*, and *L. denitrificans*.
[b] Abbreviations: Apc, ampicillin; Gen, gentamicin; Kan, kanamycin; Mino, minocycline; Str, streptomycin; Tet, tetracycline; Tei, teicoplanin; Van, vancomycin.
[c] The frequency was calculated as the number of selected transconjugants per donor cell.
[d] NT, not tested.



FIG. 1. Agarose gel electrophoresis of EcoRI-digested plasmid DNAs of bacteriocinogenic strain VRE82 and transconjugants. Lanes: 1, HindIII-digested lambda DNA; 2, *E. faecium* VRE82 (wild-type VRE strain); 3, nonbacteriocinogenic VRE BM4105RF transconjugant; 4, bacteriocinogenic VRE BM4105RF transconjugant. Arrow, 6.2-kb band.

kbp EcoRI fragment was designated pMG501. *E. faecalis* FA2-2 and *E. hirae* ATCC 9790 were transformed with pMG501. The transformants expressed bacteriocin activity identical to that of wild-type strain VRE82. These results implied that bacteriocinogenic VRE82 harbored a 6.2-kbp plasmid that conferred bacteriocin activity and had one EcoRI site. The 6.2-kbp plasmid was designated pDT1, and the bacteriocin encoded by pDT1 was designated Bac 43.

DNA sequence of pDT1. The DNA sequence of pDT1 was determined with plasmid pMG501. There was a possibility that another small EcoRI fragment lay in the gap formed by the single EcoRI site of pDT1, but this was too small to detect by agarose gel electrophoresis. PCR was also performed with the plasmid DNAs of VRE82 and the J1 and J2 primers (Table 2), which lie on either side of the single EcoRI site of pDT1 (Fig. 2). Sequence analysis of the PCR products confirmed that there was no other fragment lying in the gap formed by the EcoRI site of the 6.2-kbp plasmid. pDT1 was found to be 6,173 bp in length. Computer analysis revealed the presence of eight ORFs (ORF1 to ORF8) in pDT1, and all were oriented in the same direction. Figure 2a shows the ORFs that had a good ribosome binding site within a 20-base region upstream of the predicted start codon. Homology analysis of each ORF was performed with the DDBJ data bank. Each of the predicted proteins encoded by ORF5, ORF6, ORF8, and ORF9 showed no significant homology to the reported proteins. The ORF7 protein showed significant homology to the replication proteins of the plasmid found in gram-positive bacteria and designated the *repA* gene of pTD1. The analyses of the remaining four ORFs (ORF1 to ORF4) are described later.

Generation of Tn*5* insertion mutants. Tn*5* insertion mutant forms of the pMG501 clone containing pDT1 were generated.



FIG. 2. Physical map of pDT1 showing deduced ORFs and transposon insertions into pDT1 of pMG501 (pAM401::pDT1). (a) Physical map of pDT1 (6.2 kbp) and deduced ORFs. Thick horizontal arrows indicate ORFs on pDT1 and the direction of transcription. (b) Map of Tn*5* insertions into pDT1 of pAM401::pDT1. Open circles indicate Tn*5* insertion mutants. Numbers beside symbols are mutant identification numbers. aa, amino acids.

Fourteen insertions in pDT1 were obtained (Fig. 2b). Inserts were obtained in each of the ORFs, except ORF1 and ORF2. All of the insertion mutants expressed bacteriocin activity and immunity at the same level as wild-type pMG501 in an *E. faecium* BM4105RF background with respect to the bacteriocin activity obtained by soft-agar assay. The result implied that seven ORFs (ORF3 to ORF9) were not related to the expression of Bac 43. Although we could not exclude any potential polar effects on the adjacent gene(s) by transposon insertion, it was probable that ORF1 and ORF2 were the bacteriocin determinant.

Cloning of PCR products that confer bacteriocin production. The PCR products that corresponded to the 0- to 700-bp region of the map position and contained ORF1 and ORF2 were cloned into pAM401. Transformation of *E. faecalis* FA2-2 was performed with pAM401 carrying the PCR products. The transformants were selected on a selective agar plate containing chloramphenicol for selection of pAM401 and examined for bacteriocin activity. The results are shown in Fig. 3. pMG502 carried a 737-bp fragment and contained both ORF1 and ORF2. *E. faecalis* FA2-2 containing pMG502 expressed bacteriocin activity and immunity. pMG503 contains ORF1 and the N-terminal region of ORF2. pMG503 could not transform *E. faecalis* FA2-2. pMG504 had a deletion in the N-terminal region of ORF1 and contained the C-terminal region of ORF1 and all of ORF2. *E. faecalis* FA2-2 containing pMG504 did not express bacteriocin activity but expressed immunity. pMG505 had a deletion in the N-terminal region of ORF1 and the C-terminal region of ORF2 and contained the C-terminal region of ORF1 and the N-terminal region of ORF2. *E. faecalis* FA2-2 containing pMG505 expressed neither bacteriocin activity nor immunity. These results indicated that the fragment containing both ORF1 and ORF2 conferred bacteriocin activity and immunity on the *E. faecalis* strain.



FIG. 3. Cloning of PCR products from the region of the bacteriocin determinant of pDT1. Thick lines represent the cloned PCR product. The numbers at the ends of the thick lines represent the 5′ and 3′ ends of the segment on the map (base pairs). The vertical bar with an arrowhead is the potential promoter. a.a., amino acids; n.d., the pasmid did not transform *E. faecalis* FA2-2.

```
                                      -35              -10
  1 GAATTCAAAA CTACTTTTTA TGACGTTAAT CATTGTTATA TAATAAAATG TTATATAATA AAATTACTAA GATTATTTAA TATAACAAGC AATTTTAAAA    100

        S.D.
101 AAACGAAAAG GAAAAACAAT CATGAAAAAG AAAGTATTAA AACATTGTGT TATTCTAGGA ATATTAGGAA CTTGTCTAGC TGGCATCGGT ACAGGAATAA    200
         Primer H1         M  K  K  K  V  L  K  H  C  V  I  L  G  I  L  G  T  C  L  A  G  I  G  T  G  I      26
                        ORF1 (bacA) -->

201 AAGTTGATGC AGCTACTTAC TATGGAAATG GTCTTTATTG TAACAAAGAA AAATGTTGGG TAGATTGGAA TCAAGCTAAA GGAGAAATTG GAAAAATTAT    300
    K  V  D  A  A  T  Y  Y  G  N  G  L  Y  C  N  K  E  K  C  W  V  D  W  N  Q  A  K  G  E  I  G  K  I  I      60

                                                         S.D.
301 TGTTAATGGT TGGGTTAATC ATGGTCCATG GGCACCTAGA AGGTAGTGGT AGGGAGGTTA TTATAATGGA TTTTACTAAA GAAGAAAAAC TTTTAAATGC    400
     V  N  G  W  V  N  H  G  P  W  A  P  R  R  *                       M  D  F  T  K  E  E  K  L  L  N  A   74/12
                                                                      ORF2 (bacB) -->

401 AATTAGTAAA GTATACAATG AAGCAACTAT AGATGACTAT CCTGACTTAA AAGAAAAGCT CTTTCTTTAT TCTAAAGAAA TCAGTGAGGG AAAAAGTGTT    500
     I  S  K  V  Y  N  E  A  T  I  D  D  Y  P  D  L  K  E  K  L  F  L  Y  S  K  E  I  S  E  G  K  S  V      45

501 GGTGAAGTTA GTATGAAATT AAGTAGTTTT CTTGGAAGAT ATATTTTAAA ACATAAATTT GGATTACCTA AATCTTTAAT AGAATTACAA GAAATTGTTA    600
     G  E  V  S  M  K  L  S  S  F  L  G  R  Y  I  L  K  H  K  F  G  L  P  K  S  L  I  E  L  Q  E  I  V      78

601 GTAAGGAATC TCAAGTATAT AGAGGATGGG CTTCTATTGG TATTTGGAGT TAATTCTTTG GAATAAAATG AAAATGGGAC TGAAGAATCA ATTCTGATTC    700
    S  K  E  S  Q  V  Y  R  G  W  A  S  I  G  I  W  S  *              Primer H2    ------------->  <------    95
                                                                                           Inverted repeat

701 ATCAGTCCCA TAAATTATAG AGCCGAAAAA TTATCATATT TATAGATTTA TTAATAGTAA ATGGCATAAG AATCTTTGAA CAACGAAAAA AATGTAGCTC    800
```

FIG. 4. Nucleotide sequence of *bacA* and *bacB* of bacteriocin 43 and deduced amino acid sequence. Potential promoters (−10 and −35) and S.D. ribosome binding sequences are underlined. The inverted repeat sequence is indicated by horizontal arrows. Primers H1 and H2, which were used for PCR analysis of the bac43 determinant in clinical isolates, are indicated by dashed lines. The accession number is AB178871.

ORF1 encoded the bacteriocin, and ORF2 encoded immunity against this bacteriocin. ORF1 and ORF2 were designated *bacA* and *bacB*, respectively.

DNA sequence analysis of ORF1 (*bacA*) and ORF2 (*bacB*). A homology search of *bacA* and *bacB* was performed against the DDBJ protein database. *bacA* encoded a 74-amino-acid protein. The ATG start codon was preceded by a potential Shine-Dalgarno (S.D.) ribosome binding site (AAGGAA) at a location 9 bp upstream (Fig. 4). The deduced BacA protein had a span of hydrophobic residues typical of a signal sequence in its N-terminal region, and a potential signal peptidase processing site corresponding to the V-D-A sequence was located at positions 28 to 30 (Fig. 5). Comparison of the primary structure of the deduced amino acid sequence of the mature BacA protein, which was composed of 44 amino acid residues, showed 50 to 86% homology with the mature Bac 31 (42), enterocin SE-K4 (13), enterocin P (4), divercin V41 (30), and listerocin 743A (26) proteins, which belong to the class IIa bacteriocins produced by LAB (14, 22), and 98% homology with Bac RC714 (43 amino acids), which corresponds to a protein lacking the last amino acid residue (44th Arg) of Bac 43 (10). As with the class IIa bacteriocins, the BacA protein had a hydrophobic N-terminal region, contained the consensus sequence Tyr-Gly-Asn-Gly-Lys(Val) (YGNGL[V]), and had a relatively hydrophilic C-terminal region (Fig. 5). The putative signal sequences (30-amino-acid sequences) did not show any significant homology with any other reported proteins or leader peptides.

bacB encoded a 95-amino-acid deduced protein without a putative signal sequence. The ATG start codon was preceded by a potential S.D. ribosome binding site (AGGGAG) at a location 9 bp upstream (Fig. 4). Comparison of the primary structure of the deduced amino acid sequence of the BacB protein showed 50% and 25% homology with the immunity proteins of bacteriocin 31 and enterocin SE-K4, respectively.

```
BacA (Bac 43)  MKKKVLKHCVILGILGTCLAGIGTGIKVDAATYYGNGLYCNKEKCWVDWNQAKGEIGKIIVNGWVNHGPWAPRR   44(74) a. a.
RC714                                        ATYYGNGLYCNKEKCWVDWNQAKGEIGKIIVNGWVNHGPWAPR    43 a. a.
BacA (Bac 31)        MKKKLVICGIIGIGFTALGTNVEAATYYGNGLYCNKQKCWVDWNKASREIGKIIVNGWVQHGPWAPR    43(67) a. a.
                                             ↑
```

FIG. 5. Comparison of the amino acid sequence of the predicted BacA protein of bacteriocin 43 with the amino acid sequences of homologous bacteriocins. The sequences of the predicted BacA protein and other class IIa bacteriocins are shown. The consensus sequence Tyr-Gly-Asn-Gly-Lys (Val) (YGNGL[V]) of class IIa bacteriocins is indicated in boldfaced letters. The vertical arrow and dashed line indicate the cleavage site in the prebacteriocins. Identical amino acids (a.a.) are boxed.



FIG. 6. EcoRI-digested plasmid DNAs isolated from 21 VRE strains that showed bacteriocin activity against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes*. (A) Agarose gel electrophoresis of EcoRI-digested plasmid DNAs. (B) The gel was Southern blotted and hybridized with the *bacA* probe. Lanes: 1 and 23, HindIII-digested lambda DNA; 2 to 22, strains 74, 78, 82, 83, 94, 252, 272, 278, 319, 330, 351, 367, 418, 419, 424, 437, 455, 477, 506, 576, and 595, respectively. Arrows, 6.2-kb bands.

Identification of a Bac 43 determinant in VRE strains producing the same bacteriocin spectrum as Bac 43. Plasmid DNAs isolated from each of the 21 VRE strains that showed the same bacteriocin activity as that of Bac 43 were examined for the presence of the bac43 determinant by PCR analysis with specific primers H1 and H2 for the *bacA* and *bacB* genes of bac43, respectively. The PCR primers are shown in Table 2 and Fig. 4. The 21 strains gave rise to the expected 576-bp product of *bacA* and *bacB* by PCR analyses (data not shown). Each of the PCR products specific for the *bacA* and *bacB* genes was sequenced. The nucleotide sequences of the genes from the strains were identical to those of the genes carried by pDT1 (data not shown). These indicated that the Bac 43-type bacteriocinogenic 21 strains carried *bacA* and *bacB* of bacteriocin 43 on the plasmid. Plasmid DNAs isolated from each of the 21 VRE strains were also examined for the presence of the bac43 determinant by Southern analysis with a specific probe (Table 2). EcoRI fragments of plasmid DNAs from each of the 21 strains were separated by agarose gel electrophoresis (Fig. 6A). The gel was Southern blotted and hybridized with the bac43 determinant (Fig. 6B). The probe hybridized to a specific EcoRI fragment with a molecular size of 6.2 kbp in each of the 21 strains that had been confirmed to carry the bac43 determinant by PCR analysis and DNA sequencing.

The banding patterns obtained by pulsed-field gel electrophoresis of SmaI-digested genomic DNA(s) were used to compare the 21 strains, which showed 12 different patterns. These data suggested that the Bac 43-type bacteriocin of each of the 21 strains was encoded on a pDT1-type plasmid and that the

TABLE 4. Mobilization of Tn5 insertion mutant forms of pDT1 (pMG501::Tn5) by pHTβ[a]

# or Strain no.[b]	Plasmid	Location of Tn5 insertion	Position of insertion (bp) on pDT1 map	Transfer frequency[c]	
				Cm^r	Van^r
Vector	pAM401			$<1.0 \times 10^{-6}$	6×10^{-2}
Wild type	pMG501 (pAM401::pDT1)			9.5×10^{-4}	5×10^{-2}
1	pMG501-01	*mobC* (ORF3)	1106	$<1.0 \times 10^{-6}$	3×10^{-2}
2	pMG501-02	*mobC* (ORF3)	1420	$<1.0 \times 10^{-6}$	2×10^{-2}
3	pMG501-03	*mobA* (ORF4)	1884	$<1.0 \times 10^{-6}$	4×10^{-2}
4	pMG501-04	*mobA* (ORF4) and ORF5	2228	$<1.0 \times 10^{-6}$	6×10^{-2}
5	pMG501-05	ORF6	3197	1.2×10^{-4}	5×10^{-2}
6	pMG501-06	ORF6	3296	4.1×10^{-5}	6×10^{-2}
7	pMG501-07	Downstream of ORF6	3338	2.2×10^{-4}	8×10^{-2}
8	pMG501-08	Between ORF6 and ORF7	3535	1.1×10^{-3}	5×10^{-2}
9	pMG501-09	Between ORF6 and ORF7	3641	3.4×10^{-4}	3×10^{-2}
10	pMG501-10	Between ORF6 and ORF7	3725	2.1×10^{-4}	4×10^{-2}
11	pMG501-11	ORF7	4329	1.0×10^{-4}	4×10^{-2}
12	pMG501-12	ORF7	4730	1.2×10^{-4}	6×10^{-2}
13	pMG501-13	ORF8	5546	2.0×10^{-4}	5×10^{-2}
14	pMG501-14	ORF9	5703	4.0×10^{-4}	5×10^{-2}

[a] Mating experiments were performed with *E. faecalis* FA2-2 carrying plasmids pMG501::Tn5 and pHTβ as the donor strain and *E. faecalis* JH2SS as the recipient strain. The donor strain harbored both pHTβ (Van^r) as a mobilizer plasmid and each of the pAM401 derivatives (Cm^r) containing a Tn5 insertion mutant form of pMG501 as the tester plasmid.
[b] The pMG501 derivative numbers correspond to the insertion mutant numbers in Fig. 2b.
[c] The frequency was calculated as the number of selected transconjugants per donor cell.

pDT1-type plasmid had been disseminated among different *E. faecium* VRE strains in the clinical environment.

Identification of the mobilization determinant. To examine the determinant for the mobilization of pDT1, each of the Tn5 insertion mutant forms of pMG501 in *E. faecalis* FA2-2 shown in Fig. 2b was tested for the ability to be mobilized by the coresident vancomycin resistance-encoding conjugative plasmid pHTβ (63.7 kb) (45) (Table 4). *E. faecalis* JH2SS was used as the recipient strain. Each insertion mutant ORF, with the exceptions of ORF3 and ORF4, was mobilized by the pHTβ plasmid (Table 4). These results implied that ORF3 and ORF4 conferred the ability to mobilize the pDT1 plasmid.

DNA sequence analysis of ORF3 and ORF4 was performed by DDBJ against the protein database. ORF3 encoded a 129-amino-acid protein. The GTG start codon was preceded by a potential S.D. ribosome binding site (AGGA) at a location 13 bp upstream. ORF4 encoded a 304-amino-acid protein. The ATG start codon was preceded by an S.D. ribosome binding site (AAGGAG) at a location 12 bp upstream. Comparison of the primary structures of the deduced amino acid sequences of the ORF3 and ORF4 proteins showed 55% homology with the MobC protein encoded by *S. aureus* plasmid pRJ9 (35) and 45% homology with the MobA protein encoded by *E. faecalis* plasmid pEF1071 (2), respectively. The reported MobC and MobA proteins were the relaxosome and nickase for plasmid DNA, respectively (2, 35). ORF3 and ORF4 were designated *mobC* and *mobA*, respectively.

Identification of the mobilization determinant in 21 VRE strains producing the same bacteriocin spectrum as Bac 43. Plasmid DNAs isolated from each of the 21 VRE strains that showed the same bacteriocin activity as Bac 43 were examined for the presence of the mobilization determinant by PCR analysis with primers M1 and M2, which are specific for *mobC* and *mobA*, respectively. The PCR primers are shown in Table 2. The 21 strains gave rise to the expected 1,274-bp product by PCR analysis (not shown). This suggested that all of the 21 strains producing the same bacteriocin spectrum as Bac 43 possessed the *mobC* and *mobA* genes on a pDT1-type plasmid.

Analysis of the Bac 43 determinant in vancomycin-sensitive *E. faecium* and *E. faecalis* isolates. The plasmid DNAs of 149 vancomycin-sensitive *E. faecium* and *E. faecalis* isolates were examined for the presence of the bac43 determinant by PCR analysis with primers specific for the *bacA* and *bacB* genes of bac43. Of the 149 isolates tested, 46 *E. faecium* isolates were isolated from healthy Japanese medical students between 2002 and 2003 and 56 *E. faecium* isolates and 47 *E. faecalis* isolates were isolated at Gunma University Hospital, Japan, between 1990 and 1993. One *E. faecium* strain from a student gave rise to the expected 576-bp product and produced a bacteriocin with the same spectrum as Bac 43. The bac43 determinant was not identified in other strains.

DISCUSSION

Bac 43 was identified in the VanA-type VRE strain designated VRE82. Bac 43 was active against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes* strains and was carried by plasmid pDT1 (6.2 kbp), which was efficiently mobilized to the recipient *E. faecalis* or *E. faecium* strain at a frequency of 10^{-5} to 10^{-7} per donor cell with the coresident conjugative vancomycin resistance plasmid. The Bac 43 determinant consisted of the bacteriocin structural gene *bacA* and the immunity gene *bacB*.

The deduced mature BacA protein showed 86% homology with the mature Bac 31 protein isolated from an *E. faecalis* strain (42) and 98% homology with the mature Bac RC714 protein isolated from VRE RC714 (10). RC714 is a 43-amino-acid protein and is identical to the mature BacA protein but lacks the last residue (44th Arg) at the C-terminal region. There was no homology between the deduced amino acid sequence of the leader peptides of BacA of Bac 43 and Bac 31 (Fig. 5). The deduced BacB protein of Bac 43 showed 50%

homology with the BacB protein of Bac 31. Bac 31 is active against *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes* but is not active against *E. faecalis* (42). This implied that the six-amino-acid difference in the bacteriocin proteins of Bac 31 and Bac 43 resulted in the different bacteriocin activity spectra, as well as differences in the immunity proteins, as an adaptation in their bacteriocin activities.

Bacteriocinogenic *E. faecium* strain RC714 has been isolated from a VanA-type resistant *E. faecium* VRE clinical isolate (10). Mature Bac RC714 has been purified and characterized (10). As described above, the deduced BacA protein of Bac 43 showed 98% homology with Bac RC714 and was almost identical to RC714. Bac RC714 has been isolated only from one *E. faecium* VRE clinical isolate, and Bac 43 was also isolated only from VRE isolates, with the exception of one isolate from a healthy student. These data suggested that there would be a tendency for Bac RC714 or the Bac 43-type bacteriocin to be isolated in VRE clinical isolates than in vancomycin-sensitive isolates.

Two main types of bacteriocins were identified in the 277 (44%) bacteriocinogenic strains of the 636 VRE strains that were tested, and they were classified according to their bacteriocin activities (25). Bac 32 and Bac 32-type bacteriocins, which are active against *E. faecium*, *E. hirae*, and *E. durans* and are determined by bac32, were identified in 193 (70%) of the 277 bacteriocinogenic VRE strains (25). The other type of bacteriocin that was identified is active against *E. faecalis*, *E. faecium*, *E. hirae*, *E. durans*, and *L. monocytogenes* and was detected in 21 (3.3%) of the 277 bacteriocinogenic VRE strains (25). In this study, we showed that Bac 43 was representative of the Bac 43-type bacteriocins produced by the 21 bacteriocinogenic VRE isolates. The Bac 43 or Bac 43-type bacteriocinogenic VRE strains were the second most prevalent isolates after the Bac 32 or Bac32-type bacteriocinogenic VRE strains. However, the isolation frequency of Bac 43 or Bac 43-type bacteriocinogenic strains was far lower than that of the Bac 32 and Bac 32-type bacteriocinogenic strains. Both bacteriocins are carried by mobilizable plasmids and could be efficiently transferred to another strain by conjugative plasmids harbored by the VRE strains. The bacteriocinogenic VRE strains showed multiple-drug resistance. These characteristics indicated that Bac 32- and Bac 43-type bacteriocinogenic strains might have the same selective advantage in a clinical environment. The only difference in bacteriocin activity between Bac 43 and Bac 32 was that Bac 43 was active against *E. faecalis* and *L. monocytogenes*, whereas Bac 32 was not (25).

The well-characterized *E. faecium* bacteriocins (i.e., enterocins) are produced by food grade organisms that have been isolated from fermented foods (1, 3–6, 15, 19). Bacteriocinogenic food grade organisms are characteristically active against *L. monocytogenes* (34), which is a frequent cause of food-borne listeriosis (20). These food grade bacteriocinogenic *E. faecium* strains might have a selective advantage in their particular ecological niche. Bac 32 is not active against *L. monocytogenes* and is prevalent among the bacteriocins in *E. faecium* clinical isolates (25). The present study supports the previous hypothesis that the dominant type of bacteriocin in *E. faecium* clinical isolates might differ from the dominant type of bacteriocin found in food grade *E. faecium* isolates, which are active against *L. monocytogenes* (25).

ACKNOWLEDGMENTS

This work was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology [Tokuteiryoiki (C), Kiban (B), (C)] and the Japanese Ministry of Health, Labor and Welfare (H15-Shinko-9, H18-Shinko-11).

We thank Elizabeth Kamei for revising the manuscript.

REFERENCES

1. **Aymerich, T., H. Holo, L. S. Havarstein, M. Hugas, M. Garriga, and I. F. Nes.** 1996. Biochemical and genetic characterization of enterocin A from *Enterococcus faecium*, a new antilisterial bacteriocin in the pediocin family of bacteriocins. Appl. Environ. Microbiol. **62:**1676–1682.
2. **Balla, E., and L. M. T. Dicks.** 2005. Molecular analysis of the gene cluster involved in the production and secretion of enterocins 1071A and 1071B and of the genes responsible for the replication and transfer of plasmid pEF1071. Int. J. Food Microbiol. **99:**33–45.
3. **Casaus, P., T. Nilsen, L. M. Cintas, I. F. Nes, P. E. Hernandez, and H. Holo.** 1997. Enterocin B, a new bacteriocin from *Enterococcus faecium* T136 which can act synergistically with enterocin A. Microbiology **143:**2287–2294.
4. **Cintas, L. M., P. Casaus, L. S. Havarstein, P. E. Hernandez, and I. F. Nes.** 1997. Biochemical and genetic characterization of enterocin P, a novel *sec*-dependent bacteriocin from *Enterococcus faecium* P13 with a broad antimicrobial spectrum. Appl. Environ. Microbiol. **63:**4321–4330.
5. **Cintas, L. M., P. Casaus, H. Holo, P. E. Hernandez, I. F. Nes, and L. S. Havarstein.** 1998. Enterocins L50A and L50B, two novel bacteriocins from *Enterococcus faecium* L50, are related to staphylococcal hemolysins. J. Bacteriol. **180:**1988–1994.
6. **Cleveland, J., T. J. Montville, I. F. Nes, and M. L. Chikindas.** 2001. Bacteriocins: safe, natural antimicrobials for food preservation. Int. J. Food **71:**1–20.
7. **Clewell, D. B., and B. L. Brown.** 1980. Sex pheromone cAD1 in *Streptococcus faecalis*: induction of a function related to plasmid transfer. J. Bacteriol. **143:**1063–1065.
8. **Clewell, D. B., P. K. Tomich, M. C. Gawron-Burke, A. E. Franke, Y. Yagi, and F. Y. An.** 1982. Mapping of *Streptococcus faecalis* plasmids pAD1 and pAD2 and studies relating to transposition of Tn*917*. J. Bacteriol. **152:**1220–1230.
9. **Cox, C. R., P. S. Coburn, and M. S. Gilmore.** 2005. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr. Protein Pept. Sci. **6:**77–84.
10. **del Campo, R., C. Tenorio, R. Jiménez-díaz, C. Rubio, R. Gómez-Lui, F. Baquero, and C. Torres.** 2001. Bacteriocin production in vancomycin-resistant and vancomycin-susceptible *Enterococcus* isolates of different origins. Antimicrob. Agents Chemother. **45:**905–912.
11. **De Vuyst, L., M. R. Foulquie Moreno, and H. Revets.** 2003. Screening for enterocins and detection of hemolysin and vancomycin resistance in enterococci of different origins. Int. J. Food Microbiol. **84:**299–318.
12. **De Vuyst, L., and E. J. Vandamme.** 1994. Antimicrobial potential of lactic acid bacteria, p. 91–142. *In* L. De Vurst and E. J. Vandamme (ed.), Bacteriocins of lactic acid bacteria: microbiology, genetics and applications. Blackie Academic & Professional, London, United Kingdom.
13. **Eguchi, T., K. Kaminaka, J. Shima, S. Kawamoto, K. Mori, S.-H. Choi, K. Doi, S. Ohmomo, and S. Ogata.** 2001. Isolation and characterization of enterocin SE-K4 produced by thermophilic enterococci, *Enterococcus faecalis* K-4. Biosci. Biotechnol. Biochem. **65:**247–253.
14. **Eijsink, V. G. H., L. Axelsson, D. B. Diep, L. S. Håvarstein, H. Holo, and I. F. Nes.** 2002. Production of class II bacteriocins by lactic acid bacteria; an example of biological warfare and communication. Antonie Leeuwenhoek **82:**639–654.
15. **Floriano, B., J. L. Ruiz-Barba, and R. Jimenez-Diez.** 1998. Purification and genetic characterization of enterocin I from *Enterococcus faecium* 6T1a, a novel antilisterial plasmid-encoded bacteriocin which does not belong to the pediocin family of bacteriocins. Appl. Environ. Microbiol. **64:**4883–4890.
16. **Fujimoto, S., H. Hashimoto, and Y. Ike.** 1991. Low cost device for electrotransformation and its application to the highly efficient transformation of *Escherichia coli* and *Enterococcus faecalis*. Plasmid **26:**131–135.
17. **Gilmore, M. S., R. A. Segarra, and M. C. Booth.** 1990. An HlyB-type function is required for expression of the *Enterococcus faecalis* hemolysin/bacteriocin. Infect. Immun. **58:**3914–3923.
18. **Gilmore, M. S., R. A. Segarra, M. C. Booth, C. P. Bogie, L. R. Hall, and D. B. Clewell.** 1994. Genetic structure of the *Enterococcus faecalis* plasmid pAD1-encoded cytolytic toxin system and its relationship to lantibiotic determinants. J. Bacteriol. **176:**7335–7344.
19. **Giraffa, G.** 2002. Enterococci from foods. FEMS Microbiol. Rev. **26:**163–171.
20. **Giraffa, G.** 2003. Functionality of enterococci in dairy products. Int. J. Food Microbiol. **88:**215–222.
21. **Haas, W., B. D. Shepard, and M. S. Gilmore.** 2002. Two-component regulator of *Enterococcus faecalis* cytolysin responds to quorum-sensing autoinduction. Nature **415:**84–87.

22. **Hechard, Y., and H. G. Sahl.** 2002. Mode of action of modified and unmodified bacteriocins from gram-positive bacteria. Biochimie **84**:545–557.
23. **Ike, Y., and D. B. Clewell.** 1984. Genetic analysis of the pAD1 pheromone response in *Streptococcus faecalis*, using transposon Tn*917* as an insertional mutagen. J. Bacteriol. **158**:777–783.
24. **Ike, Y., D. B. Clewell, R. A. Segarra, and M. S. Gilmore.** 1990. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in *Enterococcus faecalis*: Tn*917* insertional mutagenesis and cloning. J. Bacteriol. **172**:155–163.
25. **Inoue, T., H. Tomita, and Y. Ike.** 2006. Bac 32, a novel bacteriocin widely disseminated among clinical isolates of *Enterococcus faecium*. Antimicrob. Agents Chemother. **50**:1202–1212.
26. **Kalmokoff, M. L., S. K. Banerjee, T. Cry, M. A. Hefford, and T. Gleeson.** 2001. Identification of a new plasmid-encoded *sec*-dependent bacteriocin produced by *Listeria innocua* 743. Appl. Environ. Microbiol. **67**:4041–4047.
27. **Leclercq, R., S. Dutka-Malen, J. Duval, and P. Courvalin.** 1992. Vancomycin resistance gene *vanC* is specific to *Enterococcus gallinarum*. Antimicrob. Agents Chemother. **36**:2005–2008.
28. **Maqueda, M., A. Galvez, M. M. Bueno, M. J. Sanchez-Barrena, C. Gonzalez, A. Albert, M. Rico, and E. Valdivia.** 2004. Peptide AS-48: prototype of a new class of cyclic bacteriocins. Curr. Protein Pept. Sci. **5**:399–416.
29. **Martinez-Bueno, M., A. Galbez, E. Valdivia, and M. Maqueda.** 1990. A transferable plasmid associated with AS-48 production in *Enterococcus faecalis*. J. Bacteriol. **172**:2817–2818.
30. **Métivier, A., M.-F. Pilet, X. Dousset, O. Sorokine, P. Anglade, M. Zagorec, J.-C. Piaed, D. Marion, Y. Cenatiempo, and C. Fremaux.** 1998. Divercin V41, a new bacteriocin with two disulphide bonds produced by *Carnobacterium divergence* V41: primary structure and genomic organization. Microbiology **144**:2837–2844.
31. **Murray, B. E., K. V. Singh, J. D. Heath, B. R. Sharma, and G. M. Weinstock.** 1990. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J. Clin. Microbiol. **28**:2059–2063.
32. **Nakamura, T., N. Yamazaki, H. Tamiguchi, and S. Fujimura.** 1983. Production, purification, and properties of a bacteriocin from *Staphylococcus aureus* isolated from saliva. Infect. Immun. **39**:609–614.
33. **Nes, I. F., D. B. Diep, L. S. Havarstein, M. B. Brurberg, V. Eijsink, and H. Holo.** 1996. Biosynthesis of bacteriocins in lactic acid bacteria. Antonie Leeuwenhoek **70**:113–128.
34. **Nes, I. F., and H. Holo.** 2000. Class II antimicrobial peptides from lactic acid bacteria. Biopolymers **55**:50–61.
35. **Netz, D. J. A., R. Pohl, A. G. Beck-Sickinger, T. Selmer, A. J. Pierik, M. C. F. Bactos, and H. G. Sahl.** 2002. Biochemical characterization and genetic analysis of aureocin A53, a new, atypical bacteriocin from *Staphylococcus aureus*. J. Mol. Biol. **319**:745–756.
36. **Sambrook, J., E. F. Fritsch, and T. Maniatis.** 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
37. **Sanger, F., S. Nicklen, and A. R. Coulson.** 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA **74**:5463–5467.
38. **Solioz, M., and M. Waser.** 1990. Efficient electrotransformation of *Enterococcus hirae* with a new *Enterococcus-Escherichia coli* shuttle vector. Biochimie **72**:279–283.
39. **Tanimoto, K., and D. B. Clewell.** 1993. Regulation of the pAD1-encoded sex pheromone response in *Enterococcus faecalis*: expression of the positive regular TraE1. J. Bacteriol. **175**:1008–1018.
40. **Tanimoto, K., and T. Iino.** 1985. Additional genes essential for replication of the mini-F plasmid from origin I. Mol. Gen. Genet. **198**:358–359.
41. **Tomich, P. K., F. Y. An, and D. B. Clewell.** 1980. Properties of erythromycin-inducible transposon Tn*917* in *Streptococcus faecalis*. J. Bacteriol. **141**:1366–1374.
42. **Tomita, H., S. Fujimoto, K. Tanimoto, and Y. Ike.** 1996. Cloning and genetic organization of the bacteriocin 31 determinant encoded on the *Enterococcus faecalis* pheromone-responsive conjugative plasmid pYI17. J. Bacteriol. **178**:3585–3593.
43. **Tomita, H., S. Fujimoto, K. Tanimoto, and Y. Ike.** 1997. Cloning and genetic and sequence analysis of the bacteriocin 21 determinant encoded on the *Enterococcus faecalis* pheromone-responsive conjugative plasmid pPD1. J. Bacteriol. **179**:7843–7855.
44. **Tomita, H., C. Pierson, S. K. Lim, D. B. Clewell, and Y. Ike.** 2002. Possible connection between a widely disseminated conjugative gentamicin resistance (pMG1-like) plasmid and the emergence of vancomycin resistance in *Enterococcus faecium*. J. Clin. Microbiol. **40**:3326–3333.
45. **Tomita, H., K. Tanimoto, S. Hayakawa, K. Morinaga, K. Ezaki, H. Oshima, and Y. Ike.** 2003. Highly conjugative pMG1-like plasmids carrying Tn*1546*-like transposons that encode vancomycin resistance in *Enterococcus faecium*. J. Bacteriol. **185**:7024–7028.
46. **Wirth, R., F. Y. An, and D. B. Clewell.** 1986. Highly efficient protoplast transformation system for *Streptococcus faecalis* and a new *Escherichia coli-S. faecalis* shuttle vector. J. Bacteriol. **165**:831–836.
47. **Yagi, Y., R. E. Kessler, J. H. Shaw, D. E. Lopatin, F. An, and S. B. Clewell.** 1983. Plasmid content of *Streptococcus faecalis* strain 39-5 and identification of a pheromone (cPD1)-induced surface antigen. J. Gen. Microbiol. **129**:1207–1215.

Applied and Environmental Microbiology, Oct. 2006, p. 6544–6553 Vol. 72, No. 10
0099-2240/06/$08.00+0 doi:10.1128/AEM.00749-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Pheromone-Responsive Conjugative Vancomycin Resistance Plasmids in *Enterococcus faecalis* Isolates from Humans and Chicken Feces

Suk-Kyung Lim,[1,3] Koichi Tanimoto,[2] Haruyoshi Tomita,[1] and Yasuyoshi Ike[1,2]*

Department of Bacteriology and Bacterial Infection Control[1] and Laboratory of Bacterial Drug Resistance,[2] Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan, and National Veterinary Research and Quarantine Service (NVRQS) 480, Anyang 6 Dong, Manangu, Anyang City 430-824, Korea[3]

Received 31 March 2006/Accepted 14 July 2006

The drug resistances and plasmid contents of a total of 85 vancomycin-resistant enterococcus (VRE) strains that had been isolated in Korea were examined. Fifty-four of the strains originated from samples of chicken feces, and 31 were isolated from hospital patients in Korea. *Enterococcus faecalis* KV1 and KV2, which had been isolated from a patient and a sample of chicken feces, respectively, were found to carry the plasmids pSL1 and pSL2, respectively. The plasmids transferred resistances to vancomycin, gentamicin, kanamycin, streptomycin, and erythromycin to *E. faecalis* strains at a high frequency of about 10^{-3} per donor cell during 4 hours of broth mating. *E. faecalis* strains containing each of the pSL plasmids formed clumps after 2 hours of incubation in broth containing *E. faecalis* FA2-2 culture filtrate (i.e., the *E. faecalis* sex pheromone), and the plasmid subsequently transferred to the recipient strain in a 10-min short mating in broth, indicating that the plasmids are responsive to *E. faecalis* pheromones. The pSL plasmids did not respond to any of synthetic pheromones for the previously characterized plasmids. The pheromone specific for pSL plasmids has been designated cSL1. Southern hybridization analysis showed that specific FspI fragments from each of the pSL plasmids hybridized with the aggregation substance gene (*asa1*) of the pheromone-responsive plasmid pAD1, indicating that the plasmids had a gene homologous to *asa1*. The restriction maps of the plasmids were identical, and the size of the plasmids was estimated to be 128.1 kb. The plasmids carried five drug resistance determinants for *vanA*, *ermB*, *aph(3')*, *aph(6')*, and *aac(6')/aph(2')*, which encode resistance to vancomycin, erythromycin, kanamycin, streptomycin, and gentamicin/kanamycin, respectively. Nucleotide sequence analyses of the drug resistance determinants and their flanking regions are described in this report. The results described provide evidence for the exchange of genetic information between human and animal (chicken) VRE reservoirs and suggest the potential for horizontal transmission of multiple drug resistance, including vancomycin resistance, between farm animals and humans via a pheromone-responsive conjugative plasmid.

Multiple-drug-resistant enterococci, and vancomycin-resistant enterococci (VRE) in particular, are a major cause of nosocomial infections. The acquired glycopeptide resistance of VanA has been predominantly identified in *Enterococcus faecium* isolates (4, 12, 13). In the United States, there is a high incidence of VanA-type *E. faecium* among human clinical isolates obtained from health care environments (46). Avoparcin has not been approved for use in animal feeds in the United States, and VRE have not been isolated outside health care environments from sources such as healthy human fecal samples or animals (12, 35). In Europe, VanA-type *E. faecium* isolates are frequently isolated outside the health care environment from materials such as sewage, food, animals, and healthy human fecal samples (4, 35); however, there is a low incidence of VRE among clinical isolates obtained from within the health care environment (35). A major factor that has contributed to the dissemination of VRE in the United States and Europe is now evident. In the United States, it is likely that the excessive use of glycopeptide antibiotics in the health care environment has resulted in the selective increase of VRE in the human intestine (25, 34), which has subsequently been spread by nosocomial transmission. In Europe, it is strongly suggested that the use of avoparcin as a growth promoter in animal feed has resulted in the selective increase of VRE in the human community (27, 49, 52). In both cases, the direct selective pressure of glycopeptides is the largest contributing factor in the selective increase of VRE in the different habitats. Korea, like many European countries, has used avoparcin for 13 years, from 1984 to 1996, as a growth promoter in food animals, including chickens, and VRE have been found in both the health care environment and chicken feces (41). In Korea, vancomycin injections have been used for treatment of infection by β-lactam-resistant gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus*, since 1992, and VRE are also frequently isolated as nosocomial pathogens from hospitalized patients (42).

Vancomycin resistance can be disseminated both by the clonal spread of resistant enterococci and by the horizontal transmission of the resistance genes. Horizontal transmission of vancomycin resistance can be explained by the fact that the VanA-type determinant is encoded on transposon Tn*1546* or a Tn*1546*-like transposon (2) that frequently resides on a conjugative plasmid in VanA-type *E. faecium* and that the plasmid is able to transfer by mating on solid surfaces (30). The pheromone-independent pMG1-like conjugative plasmids, which transfer highly efficiently between enterococcal strains during

* Corresponding author. Mailing address: Department of Bacteriology and Bacterial Infection Control and Laboratory of Bacterial Drug Resistance, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan. Phone: 81-27-220-7990. Fax: 81-27-220-7990. E-mail: yasuike@med.gunma-u.ac.jp.

TABLE 1. Bacterial strains and plasmids

Strain or plasmid	Genotype or phenotype	Description	Reference
Strains			
E. faecalis FA2-2	*rif fus*	Derivative of JH2	11
E. faecalis JH2SS	*str spc*	Derivative of JH2	44
E. faecalis OGIS	*str*	Derivative of OG1	9
E. faecium BM4105RF	*rif fus*	Derivative of plasmid-free *E. faecium* BM4105	5
Plasmids			
pAD1	*hly/bac uvr*	59.6-kb pheromone-responsive plasmid from *E. faecalis* DS16	11
pMG1	Gm^r	65.1-kb conjugative plasmid from *E. faecium* strain	28
pAM714	*hly/bac erm*	pAD1::Tn*917*; wild-type transfer	26

broth mating (28, 47), are commonly found in *E. faecium* (28, 46). The Tn*1546*-like transposon is also present on the pMG1-like conjugative *E. faecium* plasmid (45, 47).

Most pheromone-responsive plasmids are also found in *Enterococcus faecalis* (10, 15). These plasmids exhibit a narrow host range and transfer between *E. faecalis* strains at a high frequency (10^0 to 10^{-2} per donor cell) within a few hours during broth matings. The plasmids confer a mating response to a small peptide (i.e., a sex pheromone) secreted by potential recipient cells. This mating signal induces the synthesis of a surface aggregation substance that facilitates the formation of mating aggregates. Plasmid-free recipients secrete multiple sex pheromones, each specific for a donor harboring a related pheromone-responsive plasmid. Once a plasmid is acquired by the recipient, secretion of the related pheromone ceases, whereas other unrelated pheromones continue to be produced. Determinants encoded on pheromone-responsive plasmids include those for hemolysin, bacteriocin, and resistance to UV light and antibiotics, including VanA-type resistance (10, 22).

In this report, we show that identical pheromone-responsive plasmids that encode multiple drug resistance, including VanA-type resistance, were isolated from both a hospital patient and a sample of chicken feces.

MATERIALS AND METHODS

Bacteria, plasmids, media, and antibiotics. Eighty-five VRE isolates were used in the present study, with 31 (*E. faecium*, 25; *E. faecalis*, 6) isolated from hospital patients in Korea between 1998 and 2000 and 54 (*E. faecium*, 50; *E. faecalis*, 2; *Enterococcus durans*, 2) isolated from samples of chicken feces in Korea in 1998. The laboratory strains and plasmids used in the current study are listed in Table 1. The *E. faecalis* and *E. faecium* strains were grown in Todd-Hewitt Broth (Difco Laboratories, Detroit, MI) or N2GT broth (nutrient broth no. 2 [Oxoid Ltd., London, United Kingdom] supplemented with 0.2% glucose and 100 mM Tris-HCl [pH 7.5]). The N2GT broth was also used in the sex pheromone experiments. Mueller-Hinton (MH) broth and MH agar were used for the sensitivity disk agar-N (Nissui, Tokyo, Japan) assay to test the MICs of the antibiotics. The agar plates were prepared by adding 1.5% agar to the broth medium.

The antibiotics used in this study were as follows: ampicillin (Ap), chloramphenicol (Cm), erythromycin (Em), fusidic acid, gentamicin (Gm), kanamycin (Km), rifampin, spectinomycin, streptomycin (Sm), tetracycline (Tc), teicoplanin (Tei), and vancomycin (Vcm). To select for transconjugants in the mating experiments, antibiotics were used at the following concentrations: Em, 10 μg/ml; fusidic acid, 12.5 μg/ml; Gm, 125 μg/ml; Km, 500 μg/ml; rifampin, 12.5 μg/ml; spectinomycin, 125 μg/ml; Sm, 500 μg/ml; Tei, 16 μg/ml; and Vcm, 16 μg/ml.

MIC determination. The MICs of the antibiotics were determined by the agar dilution method according to the CLSI (formerly NCCLS) criteria using MH agar (36).

Mating procedures. The broth matings were performed as previously described with a donor/recipient ratio of 1:9 (28). Unless otherwise described, the broth mating was carried out for 4 h.

Solid-surface mating was performed on agar plates as described previously (23). In both mating experiments, transconjugants were counted after 48 h of incubation at 37°C. *E. faecium* BM4105RF and *E. faecalis* FA2-2 were used as recipient strains in mating experiments with VRE isolates from human and chicken feces.

Pheromone induction. The detection of aggregation (clumping) was performed as previously described (7, 15, 16). A culture filtrate of plasmid-free FA2-2 was used as the pheromone. Generally, 0.5 ml of pheromone was mixed with 0.5 ml of fresh N2GT broth and 20 μl of the overnight-cultured cells that were to be tested for the ability to respond. The mixtures were cultured for 2 to 4 h at 37°C with shaking and were examined for clumping.

Short mating induced by the pheromone was performed as follows (28). After induction, 0.1 ml of each donor strain was mixed with 0.9 ml of the recipient strain and the mixture was incubated for 10 min at 37°C. The mixture was then plated on selective plates containing the appropriate antibiotics.

Synthetic pheromone (final concentration, 100 ng/ml) in N2GT was used to replace the natural pheromone (culture filtrate of strain FA2-2) in some experiments. The synthetic pheromones were purchased from SAWADY Technology Co., Ltd. (Tokyo, Japan).

Isolation and manipulation of plasmid DNA. Plasmid DNA was isolated from 5 ml of overnight culture by the alkali lysis method (39). Lysozyme treatment (4 mg/ml for 30 min at 37°C) was performed before alkali lysis. DNA manipulation and analysis of plasmid DNA were carried out by standard protocols (3, 39).

Pulsed-field gel electrophoresis (PFGE). Lysis of cells in agarose plugs was performed according to the standard protocols (3, 39), except that the cells were treated with lysozyme at a concentration of 20 mg/ml. The reaction mixture for SmaI digestion of whole chromosomal DNA was incubated at 25°C overnight. The gels were electrophoresed with a clamped homogeneous electric field (6V/cm at 15°C for 24 h; Switch times were ramped from 1 to 25 seconds [CHEF-DR II; Bio-Rad Laboratories, Richmond, CA]) and then stained with ethidium bromide and photographed with a UV light source.

Southern hybridization. After agarose gel electrophoresis, DNAs were transferred to a nylon membrane by capillary transfer. Southern hybridization was performed using the digoxigenin-based nonradioisotope system (Roche Diagnostics GmbH, Germany), and all procedures were based on the manufacturer's manual and standard protocols (3, 39). Hybridization was performed overnight at 42°C in the presence of 50% formamide. The probes for *asa1* and the drug resistance genes were generated by PCR amplification. The nucleotide sequences of the primer pairs are shown in Table 2. PCR products were separated by agarose gel electrophoresis and purified from the agarose gel blocks with Wizard SV Gel and the PCR Clean-Up System (Promega, Madison, WI). Probes were labeled using a digoxigenin labeling kit (Roche Diagnostics GmbH), and signals were detected using a digoxigenin chemiluminescence detection kit (Roche Diagnostics GmbH).

PCR and specific primers. The sets of specific primers used in PCR amplification are listed in Table 2. A TaKaRa *Taq* (TAKARA BIO Inc., Shiga, Japan) and a Thermal Cycler Model 9600 (Perkin-Elmer, Wellesley, MA) were used for the PCRs unless otherwise stated. Long PCR was performed using an Expand Long Template PCR System (Roche Diagnostics GmbH) and a Thermal Cycler Model 9600 (Perkin-Elmer).

TABLE 2. Nucleotide sequences of PCR primers

Gene	Primer(s)	Sequence (5′-3′)	Position[a] (5′-3′)	Product size (bp)	Reference
aac(6′)-Ii	AAC6Ii/F	TGGCCGGAAGAATATGGAGA	73–92	410	32
	AAC6Ii/B	TTTGGTAAGACACCTACG	482–462		
ant(4′)-Ia	ANT4Ia/F	GGAAGCAGAGTTCAGCCATG	180–199	266	32
	ANT4Ia/B	TGCCTGCATATTCAAACAGC	445–426		
ant(9′)-Ia	ANT9Ia/F	GGTTCAGCAGTAAATGGTGGT	103–123	476	32
	ANT9Ia/B	TGCCACATTCGAGCTAGGGTT	578–557		
aph(2″)-Ic	APH2Ic/F	ATACAATCCGTCGAGTCGCT	61–80	837	32
	APH2Ic/B	GTTGGCCTTATCCTCTTCCA	897–878		
aac(6′)-aph(2″)	AAC6APH2/F	TGATGATTTTCCTTTGATGT	45–64	1,395	This study
	AAC6APH2/B	CAATCTTTATAAGTCCTTTT	1439–1420		
aph(3′)-IIIa	APH3/F	GCCGATGTGGATTGCGAAAA	454–473	292	48
	APH3/B	GCTTGATCCCCAGTAAGTCA	745–726		
ant(6′)-Ia	ANT6/F	ACTGGCTTAATCAATTTGGG	179–208	597	48
	ANT6/B	GCCTTTCCGCCACCTCACCG	775–756		
ermB	ermB-1/F	CGAAATTGGAACAGGTAAAG	102–121	546	This study
	ermB-2/B	TTCATTGCTTGATGAAACTG	647–631		
asa1	asa1-5/F	GGTGTGTTAGGAGTTGTAGG	85–104	1,115	This study
	asa/B	ATTCCATAGACAATTGTGGC	1199–1180		
vanA (Tn*1546*)	VanA-1	GCATGGCAAGTCAGGTG	7272–7288[b]	1,114	This study
	X-2	GATCAATGGCACTGCCGCG	8385–8367[b]		
ORF1 (Tn*1546*)	ORF1B1	CGTCCTGCCGACTATGATTATTT	1913–1891[b]		23
vanX (Tn*1546*)	X-1	GTAGGGACATACGAGTTGGC	8136–8155[b]		This study
vanY (Tn*1546*)	Y-REV1	CCATATATTCCTCGAGAACG	9769–9750[b]		This study
orfx (Tn*5405*)	ORFX-6/F	ATGGTAGATAATATTATTAAATCAGTAG	1–28		This study
δ (pMD101)	uk-14/F	CGCTTGGCGTTGGTACAG	502–485		This study
γ (pMD101)	orf1-4/B	ATGAGTACAGTTATTTTAGCTG	1–22		This study

[a] The positions given are from the first base of the coding sequences of the genes.
[b] The positions given are from the first base of the left inverted repeat of Tn*1546*.

DNA sequencing and computer analysis. The DNA fragments to be sequenced were amplified by long PCR, separated by agarose gel electrophoresis, and purified from the agarose gel block as described above. The PCR products purified from the agarose gel blocks were sequenced directly by the primer-walking method (33). The sequencing reactions were conducted by PCR using a Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer), and the sequences were determined using an ABI Prism 310 sequencer (Perkin-Elmer). For sequencing of the region containing the drug resistance determinants, two fragments containing *ant6*, *aph3*, *ermB*, and part of open reading frame 1 (ORF1) of Tn*1546* were amplified using two sets of primers (ANT6/F and ermB-2/B; ermB-1/F and ORF1B1). The DNA sequences of the two fragments were determined as described above. Based on the sequences obtained and the sequences of homologous genes found in the database, which were expected to lie in the flanking region, three sets of primers (ORFX-6/F and ANT6/B; uk-14/F and Y-REV1; X-1 and orf1-4/B) were designed and used for the amplification of the flanking regions by long PCR. The PCR products were purified, and the DNA sequences were determined by primer walking (33). A homology search using BLAST was performed through the NCBI website (http::/www.ncbi.nlm.nih.gov/Tools/index. html).

Nucleotide sequence accession number. The nucleotide sequence data reported here have been deposited in the DDBJ, EMBL, and GenBank nucleotide sequence databases under accession number AB247327.

RESULTS

Drug resistance VRE isolates. Eighty-five VRE isolates, 54 of which had been obtained from samples of chicken feces and 31 from hospital patients in Korea, were examined for drug resistance. All of the isolates were resistant to more than four drugs, except for one *E. faecalis* isolate that showed resistance only to vancomycin (data not shown). Of the 85 VRE isolates, the numbers and percentages of 83 strains of *E. faecium* and *E. faecalis* resistant to the drugs tested are shown in Table 3. The isolation frequencies of gentamicin- and kanamycin-resistant *E. faecium* strains from chicken fecal samples were lower than those of *E. faecium* and *E. faecalis* strains from other sources. The two *E. faecalis* strains from chicken feces showed multiple resistances to Cm, Em, Gm, Km, Sm, Tei, and Vcm, suggesting that the resistances might be encoded on a plasmid.

Plasmids of VRE isolates. Plasmid DNA was prepared from each of the 85 VRE isolates and digested by EcoRI. The digested plasmid DNAs were analyzed by agarose gel electrophoresis, and the restriction fragment patterns were compared. Of these VRE isolates, *E. faecalis* KV1 and *E. faecalis* KV2, which were isolated from a patient and from a sample of

TABLE 3. Antimicrobial drug resistances of VRE

Drug	No. of drug-resistant isolates (%)[a]			
	E. faecium		*E. faecalis*	
	From chicken (n^b = 50)	From human (n = 25)	From chicken (n = 2)	From human (n = 6)
Ap	26 (52)	24 (96)	0 (0)	0 (0)
Cm	3 (6)	7 (28)	2 (100)	1 (17)
Em	43 (86)	24 (96)	2 (100)	5 (83)
Gm	0 (0)	20 (80)	2 (100)	4 (67)
Km	1 (2)	21 (84)	2 (100)	4 (67)
Sm	50 (100)	23 (92)	2 (100)	1 (17)
Tc	50 (100)	14 (56)	1 (50)	3 (50)
Tei	50 (100)	16 (64)	2 (100)	3 (50)
Vcm	50 (100)	25 (100)	2 (100)	6 (100)

[a] The numbers in parentheses indicate the percentages of resistant isolates. The drug resistance levels (MICs) of ampicillin, chloramphenicol, erythromycin, gentamicin, kanamycin, streptomycin, tetracycline, teicoplanin, and vancomycin were equal to or greater than 8, 32, 16, 64, 1,024, 512, 8, 16, and 64 μg/ml, respectively.
[b] n, number of strains tested.



FIG. 1. Agarose gel electrophoresis of EcoRI-digested plasmid DNAs and PFGE of SmaI-digested total DNA from KV strains. (A) Agarose gel electrophoresis of EcoRI-digested plasmid DNA isolated from KV strains. Lanes: M, HindIII-digested λ DNA; 1, KV1; 2, KV2; 3, pMG1. (B) PFGE of SmaI-digested total DNAs from KV strains. Lanes: 1, KV1; 2, KV2; M, Lambda ladder PFG Marker (New England Biolabs, Beverly, MA). The numbers on the right and left indicate the sizes of molecular markers in kilobase pairs.

chicken feces, respectively, were found to harbor similar (indistinguishable and apparently identical) plasmids with respect to the EcoRI restriction profile (Fig. 1A). The two strains showed the same drug resistance levels (MICs) to vancomycin (1,024 μg/ml), teicoplanin (128 μg/ml), chloramphenicol (>512 μg/ml), gentamicin (>512 μg/ml), streptomycin (>512 μg/ml), kanamycin (>512 μg/ml), and erythromycin (64 μg/ml), but KV1 also showed resistance to tetracycline (128 μg/ml).

Pulsed-field gel electrophoresis was performed on the SmaI-digested total DNAs. As shown in Fig. 1B, the SmaI-digested patterns for the total DNAs were different, suggesting the presence of the same plasmid in different host strains.

Conjugal transfer of drug resistance. The transferability of vancomycin resistance from each of the two strains to *E. faecalis* FA2-2 or *E. faecium* BM4105RF was examined by broth mating for 4 hours. The transconjugants were selected on agar plates containing 16 μg/ml of vancomycin for the selection of the transconjugant and 12.5 μg/ml of rifampin and 12.5 μg/ml of fusidic acid for counterselection of the donor strain. The vancomycin resistance was transferred to *E. faecalis* FA2-2 at a frequency of about 10^{-3} per donor cell and was not transferred to *E. faecium* BM4105RF at a detectable frequency (less than 10^{-8} per donor cell) (Table 4). The transconjugants exhibited resistance to vancomycin, teicoplanin, gentamicin, streptomycin, kanamycin, and erythromycin. Repeated transfer experiments were performed between *E. faecalis* FA2-2 and *E. faecalis* JH2SS (Table 4). The vancomycin resistance was transferred at a frequency of about 10^{-3} per donor cell between these strains, and the transconjugants obtained in each experiment also exhibited resistance to vancomycin, teicoplanin, gentamicin, streptomycin, kanamycin, and erythromycin, suggesting that the conjugative plasmids conferred these drug resistances.

Plasmid DNA was isolated from each of the wild-type strains and the *E. faecalis* FA2-2 transconjugant. The plasmid DNA was digested with EcoRI and examined by agarose gel electrophoresis. The plasmid DNAs isolated from each of the strains were identical with respect to the EcoRI restriction profiles obtained by agarose gel electrophoresis analysis. These data suggested that each of the wild-type strains harbored a single drug resistance plasmid and that the plasmid had transferred to the recipient strain. The plasmid DNAs isolated from the transconjugant, which was derived from each of the wild-type strains, *E. faecalis* KV1 and KV2, were designated pSL1 and pSL2, respectively. The restriction map of the pSL1/pSL2 plasmid was determined by agarose gel electrophoresis of the restriction fragments. Each of the plasmid DNAs was digested with XhoI, EagI, or FspI or double digested with XhoI and EagI, XhoI and FspI, or EagI and FspI. Agarose gel electrophoresis analysis of the digested DNA's was performed to determine the cleavage sites within the plasmid. The physical maps of pSL1 and pSL2 were identical, and the molecular size of each of the plasmids was 128.1 kb (Fig. 2).

Pheromone responses of pSL1 and pSL2. The mating mixture of the donor strain, *E. faecalis* JH2SS harboring pSL1 or pSL2, and the recipient strain, *E. faecalis* FA2-2, formed a mating aggregate, and vancomycin resistance transferred efficiently to the recipient strain at a frequency of about 10^{-3} per donor cell during 4 h of broth mating (Table 4). Pheromone inductions and mating experiments were performed as described in Materials and Methods to examine the *E. faecalis* pheromone responses of pSL1/pSL2. The donor cells of *E. faecalis* JH2SS carrying pSL1 or pSL2 and *E. faecalis* OG1S carrying pSL1 or pSL2 were exposed for 2 hours to an FA2-2 culture filtrate (i.e., pheromone) to induce aggregation-mating functions before a short (10-min) mating period. The short mating was carried out between the induced or uninduced donor cells and the plasmid-free recipient *E. faecalis* FA2-2. Transconjugants were selected on agar plates containing van-

TABLE 4. Transfer frequencies of pSL plasmids in *Enterococcus*

Donor	Recipient	Transfer frequency (no. of transconjugants per donor cell)[a]
KV1	*E. faecium* BM4105RF	$<10^{-8}$
KV1	*E. faecalis* FA2-2	7×10^{-3}
KV2	*E. faecium* BM4105RF	$<10^{-8}$
KV2	*E. faecalis* FA2-2	4×10^{-3}
E. faecalis FA2-2 (pSL1)	*E. faecalis* JH2SS	1×10^{-3}
E. faecalis FA2-2 (pSL2)	*E. faecalis* JH2SS	2×10^{-3}
E. faecalis JH2SS (pSL1)	*E. faecalis* FA2-2	8×10^{-4}
E. faecalis JH2SS (pSL2)	*E. faecalis* FA2-2	7×10^{-4}

[a] Overnight cultures of 0.05 ml of donor and 0.45 ml of recipient were added to 4.5 ml of fresh N2GT, and the mixtures were incubated at 37°C with gentle agitation for 4 h. Portions of the mixed cultures were then plated on solid media with appropriate selective antibiotics. Colonies were counted after incubation for 48 h at 37°C.